

Institutional Biosafety Committee, UC Davis
Office of Environmental Health and Safety

MINUTES

January 27, 2014

Hoagland Hall Rm 130

NOTE: Next IBC meeting: 2/24/2014

Start Time: 3:03 pm

In attendance:

Philip Barruel	Voting Member, Biosafety Officer, Environmental Health and Safety
Gerhard Bauer	Voting Member, Vice-Chair, IM Div of Hematology/Oncology
Bruce Draper	Voting Member, Molecular & Cellular Biology
Angela Gelli	Voting Member, Chair, Pharmacology
Diane Hoffmann	Voting Member, School of Medicine Sponsored Programs
Fred Jacobsen	Voting Member, Public Member
Johan Leveau	Voting Member, Plant Pathology
Elizabeth Maga	Voting Member, Animal Science
Lyle Najita	Voting Member, Public Member
Victor Lukas	Voting Ex-Officio Member, Attending Veterinarian
Roger Belcourt	Voting Ex-Officio Member, Occupational Health Services

IBC support staff in attendance:

Malendia Maccree	Associate BioSafety Officer, Environmental Health and Safety
------------------	--------------------------------------------------------------

Excused:

Jill Blackwelder-Parker	Non-Voting Ex-Officio Member, Associate Vice Chancellor, Safety Services
Neil Speth	Non-Voting Ex-Officio Member, UCDMC Employee Health Services
Niki Drazenovich	Associate BioSafety Officer, Environmental Health and Safety
Ioannis Stergiopoulos	Voting Member, Plant Pathology
Nicole Corley	Voting Member, Campus Veterinary Services
Renee Tsois	Voting Member, Medical Microbiology & Immunology

Guests: NONE

I. Review of past IBC meeting minutes: December 16, 2013
APPROVED (9-0-2)

II. Announcements: NONE

III. Old Business: NONE

IV. New Business:

A. Amendments:

Amend	0883(A)	NIH: BBP	BSL: 2, no agts	Rev: pb
Title:	<u>Regulation of stem cells in autism and neurodegenerative diseases</u>			
Amendment to add:	1. New experimental method for intranasal stem cell delivery into mice			
Exp date:	04/16/2015			
	APPROVED (10-0-1)			

Amend **0980(A)** NIH: IID4a *BSL: 1, no agts* Rev: pb
 Title: Cancer risk: in vitro and in vivo studies of human adipose stem cells on primary tumor breast cancer cells / Treatment of Infantile Hemangiomas
 Amendment to add: 1. GFP positive mouse hemangioma cells
 Exp date: 08/15/2014
APPROVED (10-0-1)

B. BIO BUAs for review-see BIO generated minutes:

N	R1514	new	APPROVED (11-0-0)		Rev: nld
R	R1524	(re: 0829-01)	APPROVED (11-0-0)		Rev: nld
S/O	R1527	(re: 0668)	APPROVED (11-0-0)		Rev: nld
R	R1528	(re: 0802B)	APPROVED (10-0-1)	<i>pb abst</i>	Rev: pb
R	R1530	(re: 0739-01)	APPROVED (11-0-0)		Rev: nld
R	R1532	(re: 0731-01)	APPROVED (11-0-0)		Rev: nld
R	R1534	(re: 0366)	CONDITIONAL (10-0-1)	<i>pb abst</i>	Rev: mmm
R	R1535	(re: 0613)	APPROVED (10-0-1)	<i>pb abst</i>	Rev: pb
N	R1542	new	APPROVED (11-0-0)		Rev: mmm
S/O	R1546	(re: 0655-02)	APPROVED (11-0-0)		Rev: nld
R	R1523	(re: 0823)	APPROVED (11-0-0)		Rev: mmm
R	R1526	(re: 0662)	APPROVED (11-0-0)		Rev: nld

V. Discussion Items: NONE

VI. Information Items:

1. Philip - CDPH Medical Waste inspection on February 3rd
2. Philip - USDA Select Agent Inspection is now closed
3. Philip - IBC Operating Procedures – change to include alternate IBC members this will be shown to the IBC at the February 24, 2014 meeting for a vote.

VII. IBC Training: NONE

VIII. BSL3 Laboratory Information: NONE

IX. Notifications: NONE

X. Subcommittee Topics: NONE

End Time: 4:27 p.m.

Institutional BioSafety Committee

Minutes for 01/27/2014

Final

UC Davis

Environmental Health and
Safety

Phone : (530) 752 1493

Fax : (530) 752 4527

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1527	JOHN MADIGAN	VM: MEDICINE & EPIDEMIOLOGY	New	BSL: 1 ABSL:

Action: Approved**Review Stage:** Completed**Project Title** Anaplasma phagocytophilum

Motion

Reviewer	Biostaff
Review date	December 10, 2013
Comments	1. Assign to nld 12/10, 2. finalized 12/30/13

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1530		MED: PHARMACOLOGY	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Molecular mechanisms of nervous system development and function

Motion

Reviewer	Biostaff
Review date	December 10, 2013
Comments	1. Assign to nld 12/10/13, 2. Qs sent to PI 12/30, 3. BUA finalized 1/14

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3b-lentivirus IIID4b-lentivirus in mice
IIIF	IIIF8 (App CI)- Viral vector in tissue culture IIIF8 (App CII) - E. coli K12

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1532		MED:MEDICAL MICROBIOLOGY & IMM	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Mosquito-malaria parasite interactions

Motion

Reviewer	IBC
Review date	January 27, 2014
Comments	BBP ECP needed in the attachments section.
Reviewer	Biostaff
Review date	January 7, 2014
Comments	1. Assign to nld 1/7, 2. Em Qs to PI 1/11, 3. BUA finalized 1/19

Applicable NIH Guidelines

Section	Explanation
IIID	IIID4b (rDNA in animals, tg mosquitoes)
IIIF	IIIF8 (App CII) - E. coli K12

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1534	WILLIAM LUCAS	PLANT BIOLOGY	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Functional analysis of cucurbit phloem proteins and RNA as long-distance signaling molecules

Motion

Reviewer	Biostaff
Review date	January 29, 2014
Comments	Principal Investigator addressed questions on 1/28/14. Responses reviewed and accepted by IBC member on 1/29/14. Final IBC approval letter issued 2/4/14.
Reviewer	IBC
Review date	January 27, 2014
Comments	IBC reviewers request that PI address the following points: 1. Section 7, Risk Assessment: More detailed information is requested for the genes of interest. 2. Section 10, Authorized Personnel: Lab personnel authorized to work with plants must be designated in the BUA.
Reviewer	Biostaff
Review date	January 18, 2014
Comments	Formatting changes and minor corrections made by Biostaff (MMaccree) Confirmed host species in use with PI (removed tomato and clarify use of watermelon)
Reviewer	Biostaff
Review date	December 17, 2013
Comments	1. Assigned to mmm 12/17/13; 3. Questions to PI and PI response 1/16/14

Applicable NIH Guidelines

Section	Explanation
IIIE	IIIE2a - Disarmed Agrobacterium with whole plants, IIIE - E. coli BL21
IIIF	IIIF8 Appendix CII - E. coli K12 (cloning strains)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1523		MICROBIOLOGY	New	BSL: 2 ABSL: 1

Action: Approved

Review Stage: Completed

Project Title Analysis of genes involved in mammalian meiosis

Motion

Reviewer	Biostaff
Review date	January 27, 2014
Comments	Update from PI: Work with human cells has not yet commenced, but is planned for near future once all requirements are met. Medical waste plan, BBP plan, and work site (lab) are ready for use. Workers will complete required training (Med waste/Biosafety and Safe use of BSC) before working with human cells.
Reviewer	IBC
Review date	January 27, 2014
Comments	Note: Employees who work with human cell lines must complete required training before initiating work with human cells.
Reviewer	Biostaff
Review date	January 21, 2014
Comments	Contacted PI with questions regarding use of human cells.
Reviewer	Biostaff
Review date	January 7, 2014
Comments	1. Assign to mmm 1/7

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3e - baculovirus in cell culture
IIIF	IIIF8: Appendices CI - plasmids in cell lines, CII - E. coli K-12, CIII - S. cerevisiae, CVII - transgenic mice

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1526		MED: BIOCHEM & MOLECULAR MED	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Modulation of the ErbB receptors

Motion

Reviewer	Biostaff
Review date	January 6, 2014
Comments	1. Assigned to nld 1/6/14, 2. Em Qs to , 4. BUA finalized 1/21

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3b-lentiviral work IIID3e-retroviral work IIID4b-putting viral vectors/transduced cells into animals
IIIF	IIIF8 (App CI) - recombinant DNA in tissue culture IIIF8 (App CII) - K12 IIIF8 (App CIII) - <i>S. cerevisiae</i>

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1542	KENDRA BAUMGARTNER	PLANT PATHOLOGY	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Wood-infecting fungal pathogens of grapevine

Motion

Reviewer	IBC
Review date	January 27, 2014
Comments	
Reviewer	Biostaff
Review date	January 18, 2014
Comments	<p>Formatting changes made by Biostaff (MMaccree)</p> <p>Questions for PI (PI response, actions taken):</p> <p>1. Is a permit required? (PI has contacted Stephen Brown of CDFA who is currently out of office. PI will acquire permit if required and upload copy to BIO when available. Specific note added to Risk Assessment.)</p> <p>2. Is an cloning of DNA occurring? (PI confirmed--no cloning occurring. Specific note added to Risk Assessment.)</p>
Reviewer	Biostaff
Review date	January 6, 2014
Comments	<p>1. Assigned to mmm 1/6/14</p> <p>2. Contacted PI with questions/update 1/8/14</p> <p>3. Sent final questions to PI 1/15/14</p>

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1514	DANIELA BARILE	FOOD SCIENCE & TECHNOLOGY	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Investigation of molecules in human milk, blood, urine, feces, gastric samples and intestinal samples

Motion

Reviewer	Biostaff
Review date	December 19, 2013
Comments	1. Em Qs to lab 12/19, 2. assign to nld 1/7/14, 3. Em Qs to lab 1/8, 4. Em PI 1/14/14, 5. BUA finalized 1/14

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1535		MED: DIV OF INTERNAL MED	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Molecular and Cellular Characterization of Sphingomyelinase, A Regulator of the Ceramide Pathway and Apoptosis in the Lung

Motion

Reviewer	Biostaff
Review date	December 18, 2013
Comments	1. Assign to PB 12/18/13 2. Pre-review by PB 1/16/2013

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3b (lenti), IIID3e (baculo)
IIIF	IIIF8 (App CII)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1524		VM: PATHOLOGY MICRO & IMMUN	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Bacterial induced myelosuppression in a mouse model of A. phagocytophilum infection

Motion

Reviewer	Biostaff
Review date	December 17, 2013
Comments	1. Assign to nld 12/17/13, 2. Q sent to lab contact 12/30, 3. BUA finalized 1/14/14

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1528	SUSAN ZUNINO	NUTRITION	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Anti-cancer and anti-inflammatory activities of phytochemicals

Motion

Reviewer	Biostaff
Review date	December 5, 2013
Comments	1. Assigned to PB 2. PB preview - 1/7/2014 - send BUA to IBC

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1546	NICOLE BAUMGARTH	VM: PATHOLOGY MICRO & IMMUN	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Storage only: Streptococcus pneumoniae isolates

Motion

Reviewer	Biostaff
Review date	January 9, 2014
Comments	1. Set up BUA and em PI 1/9

Applicable NIH Guidelines

Section	Explanation
None Apply	

Institutional Biosafety Committee, UC Davis
Office of Environmental Health and Safety

MINUTES

February 24, 2014 (3-5p)

Hoagland Hall Rm 130

NOTE: Next IBC meeting: 3/17/2014

Start Time: 3:03pm

In attendance:

Philip Barruel	Voting Member, Biosafety Officer, Environmental Health and Safety
Gerhard Bauer	Voting Member, Vice-Chair, IM Div of Hematology/Oncology
Nicole Corley	Voting Member, Campus Veterinary Services
Bruce Draper	Voting Member, Molecular & Cellular Biology
Angela Gelli	Voting Member, Chair, Pharmacology
Diane Hoffmann	Voting Member, School of Medicine Sponsored Programs
Elizabeth Maga	Voting Member, Animal Science
Lyle Najita	Voting Member, Public Member
Ioannis Stergiopoulos	Voting Member, Plant Pathology
Roger Belcourt	Voting Ex-Officio Member, Occupational Health Services

IBC support staff in attendance:

Niki Drazenovich	Associate BioSafety Officer, Environmental Health and Safety
Malendia Maccree	Associate BioSafety Officer, Environmental Health and Safety

Excused:

Renee Tsolis	Voting Member, Medical Microbiology & Immunology
Jill Blackwelder-Parker	Non-Voting Ex-Officio Member, Associate Vice Chancellor, Safety Services
Neil Speth	Non-Voting Ex-Officio Member, UCDMC Employee Health Services
Fred Jacobsen	Voting Member, Public Member
Johan Leveau	Voting Member, Plant Pathology
Victor Lukas	Voting Ex-Officio Member, Attending Veterinarian

Guests: None

I. Review of past IBC meeting minutes: Jan. 27, 2014

APPROVED (9-0-1) NC abstained

II. Announcements:

1. Introduction of Ioannis Stergiopoulos

III. Old Business: NONE

IV. New Business:

A. Amendments:

Amend	0769(B)	Inf agts (zoonotic)	BSL: 2, RG: 2	Rev: nld
Title:	<u>Macaques as a model for influenza and AIDS pathogenesis, transmission, vaccine development and antiviral therapy</u>			

Amendment to add: In vivo experiments (host: macaques): 1- Single infection of HSV2, 2-Co-infection of HSV2 with SIV

Exp date: 04/16/2016

APPROVED (10-0-0)

Amend **0859-01(A)** NIH: IID4a **BSL: 1 (no agts)** Rev: nld

Title: Role of protein-tyrosine phosphatases and their targets in the pathogenesis of obesity and diabetes

Amendment to add: Sleeping beauty transposon delivery to mice

Exp date: 07/18/2014

APPROVED (10-0-0)

Amend **0892(A)** BBP (human stem cells) **BSL: 2 (no agts)** Rev: pb

Title: Electric fields directed cell migration and wound healing and regeneration

Amendment to add: Injection of human stem cells into brains of anesthetized rats

Exp date: 08/20/2015

APPROVED (9-0-1) PB abstained

Amend **0978(A)** NIH: IID3b(lenti) **BSL: 2, RG: 2** Rev: pb

Title: The effects of altered cellular zinc homeostasis on body weight regulation, diabetes development, and cancer risk

Amendment to add: Lentiviral particles expressing shRNA used to transduce rodent cell lines

Exp date: 07/18/2014

CONDITIONAL (9-0-1) PB abstained

1. Specify which viral envelope will be used for the viral vector

B. BIO BUAs for review see BIO generated minutes:

R **R1511** (replacing 0959) **TABLED** Rev: mmm

- More information is requested regarding the scale of the experiment proposed (e.g., number and size of plants inoculated) and the typical volume or mass of contaminated waste expected from this work (e.g., contaminated water effluent and sand).
- 1.

R **R1518** (replacing 0963B) **APPROVED (10-0-0)** Rev: nld

R **R1525** (replacing 0829-03) **APPROVED (10-0-0)** Rev: nld

N **R1529** **CONDITIONAL (10-0-0)** Rev: mmm

1. Clarify seed handling in greenhouse and lab (e.g., when and where dry seeds are handled and when are seeds suspended in liquid to aid in control and planting operations).
2. Describe measures taken to prevent seeds from being accidentally tracked out the lab on employee shoes or clothing.
3. Describe means of assuring containment of seed if primary container is compromised or opens in transport.

R **R1536** (replacing 0915-02B) **CONDITIONAL (9-0-1) PB abst.** Rev: pb

1. Section 7, Risk Assessment: Clarify if xenographic culture will be done in a BSC.
2. Section 7, Risk Assessment: Clarify if the animals will be anesthetized during administration of the cells.

R **R1538** (replacing 0840) **CONDITIONAL (9-0-1) PB abst.** Rev: pb

1. Section 7, Risk Assessment: There is a statement about using 10% bleach for decontamination, but it didn't state what will be decontaminated. Please clarify.

R R1541 (replacing 0666) **APPROVED (10-0-0)** Rev: nld

R R1547 (replacing 0630) **APPROVED (9-0-1) PB abst.** Rev: pb

R R1551 (replacing 0637B) **APPROVED (10-0-0)** Rev: nld

R R1556 (replacing 0960) **CONDITIONAL (9-0-1) PB abst.** Rev: pb

1. Section 7, Risk Assessment: Please clarify what will be done with the vector.
2. Section 7, Risk Assessment: Please elaborate on how the risks will be mitigated.

R R1558 (replacing 0691) **APPROVED (10-0-0)** Rev: nld

R R1560 (replacing 0838) **CONDITIONAL (9-0-1) PB abst.** Rev: pb

1. Section 7, Risk Assessment: Please clarify which packaging cell is used with the viral vectors (MECV and lentiviral vector).
2. Section 7, Risk Assessment: Please clarify what will be the envelope of the lentiviral vector.

R R1562 (replacing 0834) **CONDITIONAL (10-0-0)** Rev: mmm

1. Confirm disposal and risk minimization information for experimental materials (information was accidentally omitted from BUA renewal).

N R1563 **APPROVED (10-0-0)** Rev: nld

R R1564 (replacing 0074) **APPROVED (9-0-1) PB out** Rev: mmm

R R1565 (replacing 0962B) **APPROVED (9-0-1) PB out** Rev: mmm

C. Conditional BUAs reviewed by ABSO, Final Approval by BSO:

N BUA No. C1491 NIH: IIIC Rev: mmm
 Title: BB-IND 12154 (the BOND Protocol): An Integrated Phase II/III, Open Label, Randomized, Parallel and Controlled Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients With Non-Muscle Invasive Bladder Carcinoma In Situ Disease ('NMIBCis', Meaning Cis and Cis with Ta and/or T1) and Who Have Failed BCG Therapy and Refused Cystectomy [Protocol Version: 06.10.13 (Revision 2.2)]

Conditional Date: 10/21/2013

D. Terminated BUAs:

BUA No. 0367-01B Rev: nld
 Title: Human Eye Lens

BUA No. 0367-02B Rev: nld
 Title: Cell testing on Alzheimer's related brain cells and cancer cell testing of novel therapeutics

BUA No. 0968 Rev: nld

Title: Rat glioma therapy using anti-microRNA

BUA No. **0902**

Rev: nld

Title: Reciprocal interactions between host behaviors, steroid hormones and parasites

BUA No. **0971B**

Rev: nld

Title: Effects of statins on endometrium and role of mevalonate pathway in Thecal-interstitial cell function

V. Discussion Items:

1. Philip - Discuss PPE policy in LHAT
2. Philip - vote on alt. member policy change on IBC P&P. **APPROVED (9-0-0)**

VI. Information Items: NONE

VII. IBC Training: NONE

VIII. BSL3 Laboratory Information:

1. PB - Approve BSL3 facilities for [REDACTED]

IX. Notifications:

1. List notifications

X. Subcommittee Topics:

1. List subcommittee topics

End Time: 5:40pm

Institutional BioSafety Committee

Minutes for 02/24/2014

Final

UC Davis

Environmental Health and
Safety

Phone : (530) 752 1493

Fax : (530) 752 4527

Track 3: Subcommittee Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1511	LORENCE OKI	PLANT SCIENCES	New	BSL: 1 ABSL:

Action: N/A**Review Stage:** PI Revise**Project Title** Slow sand and vegetated filters for the removal of plant pathogens

Motion

Reviewer	IBC
Review date	February 24, 2014
Comments	<p>This BUA could not be approved during the 2/24/14 IBC meeting due to the following two issues:</p> <ol style="list-style-type: none">1. Unclear jurisdiction--IBC reviewers requested confirmation from the biosafety office that UCD IBC can approve BUAs for work at [REDACTED] conducted by UCD faculty. (Brian Oatman UC-ANR EHS director, confirmed in 2/25/14 emails that UCD IBC is authorized to review this work.)2. More detailed information is required to form a risk assessment for the work conducted at South Coast Research and Extension Center. More detail is requested regarding the scale of the experiment proposed (e.g., number and size of plants inoculated) and the typical volume or mass of contaminated waste expected from this work (e.g., contaminated water effluent and sand).
Reviewer	Biostaff
Review date	January 14, 2014
Comments	<ol style="list-style-type: none">1. Assign to mmm 1/132. Questions to PI 2/10/14

Applicable NIH Guidelines

Section	Explanation
IIIF	No work conducted with nucleic acids IBC review required for plant pathogen.

Track 3: Subcommittee Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1564	ROGER CHETELAT	PLANT SCIENCES	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Deciphering mechanisms of prezygotic reproductive isolation in Solanum

Motion

Reviewer	IBC
Review date	February 24, 2014
Comments	APPROVED (9-0-1) PB out
Reviewer	Biostaff
Review date	February 4, 2014
Comments	1. Assign to mmm 2. contacted PI about BUA 2-13-14

Applicable NIH Guidelines

Section	Explanation
IIIE	IIIE2a - use of Agrobacterium with plants
IIIF	IIIF8 (Appendices CII and CIII) - use of E. coli K12 strains and S. cerevisiae

Track 2: EH&S Review Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1565		CHEMISTRY	New	BSL: 2 ABSL: 1

Action: Approved

Review Stage: Completed

Project Title Nanostructure-Enabled Chemotherapy through X-ray Activation for Breast Cancer Treatment

Motion

Reviewer	IBC
Review date	February 24, 2014
Comments	APPROVED (9-0-1) PB out
Reviewer	Biostaff
Review date	February 4, 2014
Comments	1. Assign to mmm

Applicable NIH Guidelines

Section	Explanation
None Apply	

Track 1: EH&S Approval Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1529	JOHANNA SCHMITT	EVOLUTION & ECOLOGY	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Phenotypic evaluation of mutants and natural variants of genes controlling life history traits in *Arabidopsis thaliana*

Motion

Reviewer	Biostaff
Review date	April 1, 2014
Comments	PI revised BUA to address IBC reviewers questions and concerns (4-1-2014).
Reviewer	IBC
Review date	February 24, 2014
Comments	<p>Conditional approval (10-0-0)</p> <p>IBC reviewers request that the following information be clarified in the risk assessment section of the BUA:</p> <ol style="list-style-type: none"> 1. Describe measures taken to assure that seeds are not accidentally carried out of the lab on worker clothing or shoes (e.g., use of dedicated seed harvesting area, use of dedicated PPE for seed handling, use of floor mats, etc.). 2. Clarify seed handling activities in the greenhouse to indicate whether the seed is handled dry or suspended in liquid. 3. Describe use of a secondary containment for preventing seed dispersal if primary seed container breaks or comes open during transport outside of the lab. <p>The above issues must be addressed before BUA can receive final approval.</p>
Reviewer	Biostaff
Review date	February 4, 2014
Comments	1. Assign to mmm. 2. sent questions to PI 2-13-14

Applicable NIH Guidelines

Track 1: EH&S Approval Update

Section	Explanation
IIIE	<p>IIIE2a-Experiments are conducted with plants modified by recombinant or synthetic nucleic acid molecules, but the plants are not noxious weeds or cannot interbreed with noxious weeds in the immediate geographic area.</p> <p>Experiments are conducted with plants associated with recombinant or synthetic nucleic acid molecule-modified exotic microorganisms that have no recognized potential for serious detrimental impact on managed or natural ecosystems.</p>

Track 1: EH&S Approval Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1562	CAI-ZHONG JIANG	PLANT SCIENCES	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Regulation of plant development and senescence

Motion

Reviewer	Biostaff
Review date	March 3, 2014
Comments	Dr. Jiang confirmed risk minimization and disposal practices. Risk assessment and project summary were revised accordingly.
Reviewer	IBC
Review date	February 24, 2014
Comments	<p>CONDITIONAL (10-0-0)</p> <p>IBC reviewers request that the following information be clarified in the risk assessment section of the BUA:</p> <p>1. Describe risk minimization measures and disposal practices for the work (information was inadvertently omitted with renewal in online system).</p> <p>The above issues must be addressed before BUA can receive final approval.</p>
Reviewer	Biostaff
Review date	February 4, 2014
Comments	1. Assign to mmm

Applicable NIH Guidelines

Section	Explanation
IIIE	IIIE2a-Agrobacterium in plants, IIIE-tobacco rattle virus vector in Agrobacterium

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1525		VM: PATHOLOGY MICRO & IMMUN	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Bacterial interactions with mammalian cell lines: cellular activation, regenerative capacity, and immune modulation

Motion

Reviewer	IBC
Review date	February 24, 2014
Comments	Approved (10-0-0)
Reviewer	Biostaff
Review date	February 4, 2014
Comments	1. Assign to nld, 2. Em Qs to PI 2/10, 3. BUA finalized 2/14

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1518		BIOMEDICAL ENGINEERING	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title In vitro and in vivo evaluation and imaging of delivery vehicle targeting, accumulation, biodistribution, drug release and therapeutic efficacy in tumor cancer models and endothelial cells for various disease models

Motion

Reviewer	IBC
Review date	February 24, 2014
Comments	Approved (10-0-0)
Reviewer	Biostaff
Review date	February 4, 2014
Comments	1. Assign to nld, 2. Em Qs to PI 2/10, 3. BUA finalized 2/14

Applicable NIH Guidelines

Section	Explanation
IIID	NIH Guidelines III-D-4a:

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1547		MED: UROLOGY	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Functional study of aberrantly expressed miRNAs in prostate cancer

Motion

Reviewer	IBC
Review date	February 24, 2014
Comments	APPROVED (9-0-1) PB abst.
Reviewer	Biostaff
Review date	January 14, 2014
Comments	1. Assign to pb 2. Pre-review (2/17/2014).

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1560		MED: UROLOGY	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Cytokine and androgen receptor signaling in prostate cancer

Motion

Reviewer	Biostaff
Review date	April 11, 2014
Comments	BSO confirmed that PI addressed questions
Reviewer	IBC
Review date	February 24, 2014
Comments	<p>CONDITIONAL (9-0-1) PB abst.</p> <p>Questions to be addressed:</p> <p>Section 7, Risk Assessment: Please clarify which packaging cell is used with the viral vectors (MECV and lentiviral vector).</p> <p>Section 7, Risk Assessment: Please clarify what will be the envelope of the lentiviral vector.</p>
Reviewer	Biostaff
Review date	January 22, 2014
Comments	<p>1. Assign to pb 1/22</p> <p>2. Pre-review (2/17/2014).</p>

Applicable NIH Guidelines

Section	Explanation
IIID	IIID4a (retroviral vector, lentiviral vector)
IIIF	IIIF8 (App CII)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1551	CARL KEEN	NUTRITION	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Investigating the influence of dietary components on human health

Motion

Reviewer	IBC
Review date	February 24, 2014
Comments	APPROVED (10-0-0)
Reviewer	Biostaff
Review date	February 4, 2014
Comments	1. Assign to nld, 2. Em Qs to PI 2/10, 3. Finalize BUA 2/14

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3b (lenti)
IIIF	IIIF8 App CI (vv in tc) and CII (E. coli K12)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1563		MED: NEUROLOGY	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Regulation of NMDA receptors

Motion

Reviewer	IBC
Review date	February 24, 2014
Comments	APPROVED (10-0-0)
Reviewer	Biostaff
Review date	February 5, 2014
Comments	1. Assign to nld, 2. Em Qs to PI 2/10, 3. BUA finalized 2/14

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3e - aav III-D4a - rD in animals
IIIF	IIIF-8 Appendix C1 (vv in tc), C2 (E. coli K12)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1541		VM: SURG/RAD SCIENCE	New	BSL: 1 ABSL: 1

Action: Approved

Review Stage: Completed

Project Title Studies with FHV-1 and other herpesviruses

Motion

Reviewer	IBC
Review date	February 24, 2014
Comments	APPROVED (10-0-0)
Reviewer	Biostaff
Review date	February 4, 2014
Comments	1. Assign to nld, 2. Send Qs to pi and lab contact 2/10

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1558	KYRIA BOUNDY-MILLS	FOOD SCIENCE & TECHNOLOGY	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Phaff Yeast Culture Collection, Boundy-Mills laboratory

Motion

Reviewer	IBC
Review date	February 24, 2014
Comments	APPROVED (10-0-0)
Reviewer	Biostaff
Review date	January 22, 2014
Comments	1. Assign bua to nld, 2. Send Qs to PI 2/10, 3. BUA finalized 2/14

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1536	TIANHONG LI	MED: DIV OF INTERNAL MED	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Targeting Signal Transduction Pathways in Lung Cancer

Motion

Reviewer	Biostaff
Review date	March 17, 2014
Comments	BSO confirmed that PI addressed issues.
Reviewer	IBC
Review date	February 24, 2014
Comments	CONDITIONAL (9-0-1) PB abst. Questions to address: Section 7, Risk Assessment: Clarify if xenographic culture will be done in a BSC. Section 7, Risk Assessment: Clarify if the animals will be anesthetized during administration of the cells.
Reviewer	Biostaff
Review date	February 5, 2014
Comments	1. Assign to pb 2. PB sent questions to PI and lab contact (2/8/2014)

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1538		MED: DIV OF INTERNAL MED	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title NADPH oxidases in liver fibrosis

Motion

Reviewer	Biostaff
Review date	March 17, 2014
Comments	BSO confirmed that PI addressed questions
Reviewer	IBC
Review date	February 24, 2014
Comments	CONDITIONAL (9-0-1) PB abst. Questions to be addressed: Section 7, Risk Assessment: There is a statement about using 10% bleach for decontamination, but it didnt state what will be decontaminated. Please clarify.
Reviewer	Biostaff
Review date	February 5, 2014
Comments	1. Assign to pb 2. PB pre-review questions (2/17/2014).

Applicable NIH Guidelines

Section	Explanation
IIID	IIID4a - adenoviral vectors IIID1b - lentiviral vectors IIID4a - Viral vectors will be injected to mice.
IIIF	IIIF8 (App. CII) - E. coli K-12 strain

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1556	SHEILA DAVID	CHEMISTRY	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Recognition and repair of mismatched DNA by MUTYH

Motion

Reviewer	Biostaff
Review date	March 17, 2014
Comments	BSO confirmed that PI addressed questions
Reviewer	IBC
Review date	February 24, 2014
Comments	<p>CONDITIONAL (9-0-1) PB abst.</p> <p>Question to be addressed:</p> <p>Section 7, Risk Assessment: Please clarify what will be done with the vector.</p> <p>Section 7, Risk Assessment: Please elaborate on how the risks will be mitigated.</p>
Reviewer	Biostaff
Review date	January 22, 2014
Comments	<p>1. Assign BUA to pb 1/22</p> <p>2. Pre-review (2/17/2014).</p>

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3e (baculo)
IIIF	IIIF8 (App CII)

Institutional Biosafety Committee, UC Davis
Office of Environmental Health and Safety

MINUTES

March 17 2014 (3-5p)

Hoagland Hall Rm 130

NOTE: Next IBC meeting: 4/21/2014

Start Time: 3:05pm

In attendance:

Philip Barruel	Voting Member, Biosafety Officer, Environmental Health and Safety
Nicole Corley	Voting Member, Campus Veterinary Services
Angela Gelli	Voting Member, Chair, Pharmacology
Elizabeth Maga	Voting Member, Animal Science
Lyle Najita	Voting Member, Public Member
Ioannis Stergiopoulos	Voting Member, Plant Pathology
Renee Tsolis	Voting Member, Medical Microbiology & Immunology
Roger Belcourt	Voting Ex-Officio Member, Occupational Health Services
Victor Lukas	Voting Ex-Officio Member, Attending Veterinarian

IBC support staff in attendance:

Malendia Maccree	Associate BioSafety Officer, Environmental Health and Safety
Chips Hoai	Associate BioSafety Officer, Environmental Health and Safety

Excused:

Diane Hoffmann	Voting Member, School of Medicine Sponsored Programs
Fred Jacobsen	Voting Member, Public Member
Gerhard Bauer	Voting Member, Vice-Chair, IM Div of Hematology/Oncology
Bruce Draper	Voting Member, Molecular & Cellular Biology
Johan Leveau	Voting Member, Plant Pathology
Jill Blackwelder-Parker	Non-Voting Ex-Officio Member, Associate Vice Chancellor, Safety Services
Neil Speth	Non-Voting Ex-Officio Member, UCDMC Employee Health Services
Niki Drazenovich	Associate BioSafety Officer, Environmental Health and Safety

Guests: None

I. Review of past IBC meeting minutes: None

II. Announcements:

1. Introduction of Chips Hoai

III. Old Business: NONE

IV. New Business:

A. Amendments:

Amend	0544-02(B)	Inf agts (zoonotic)	Reviewer: nld
Title:	<u>Molecular ecology of avian influenza viruses in wild birds and mammals</u>		
Amendment to add:	Fecal swabs (from various avian species) will be cultured on CVA agar to isolate <i>Campylobacter jejuni</i>		
Exp date: 08/20/2015			
APPROVED (9-0-0)			

Amend	1047(A)	IIID4a	Reviewer: nld
Title:	<u>Stem and progenitor cell isolation, culturing and application in extracellular matrix</u>		

Amendment to add: Transplant lentiviral transformed cells into rats
Exp date: 04/15/2016
APPROVED (9-0-0)

B. BIO BUAs for review see BIO generated minutes:

BSL2

- R **R1574** (replacing 0845) **APPROVED (8-0-1) PB abst.** Rev: pb
- R **R1580** (replacing 0727) **APPROVED (8-0-1) PB abst.** Rev: pb
- R **R1583** (replacing 1006B) **TABLED (No vote taken)** Rev: mmm
1. Please provide more details regarding downstream use of the viral vector.
- R **R1584** (replacing 0837) **APPROVED (8-0-1) PB abst.** Rev: pb
- R **R1591** (replacing 0347-03) **CONDITIONAL (9-0-0)** Rev: nld
1. Please clarify use of animal serum (e.g., rabbit serum).

BBP only

- R **R1568** (replacing 0660) **APPROVED (8-0-1) PB abst.** Rev: pb
- R **R1570** (replacing 0965B) **APPROVED (9-0-0)** Rev: mmm
- R **R1572** (replacing 0967) **APPROVED (8-0-1) PB abst.** Rev: pb
- R **R1576** (replacing 0935) **APPROVED (9-0-0)** Rev: nld

BSL1

- R **R1544** (replacing 0321) **APPROVED (9-0-0)** Rev: mmm
- N **R1566** **CONDITIONAL (9-0-0)** Rev: mmm
1. Section 7, risk assessment: Describe potential consequences if the corn seed were to become mixed with non-GMO corn or accidentally released to the environment.
- Section 7, risk assessment: Describe pest control and insect exclusion practices used in the
2. greenhouse or indicate why insects would be unlikely risks for pollen flow from experimental corn inside of a greenhouse.
- R **R1586** (replacing 0902) **CONDITIONAL (9-0-0)** Rev: nld
- Please describe how infectious agents remaining in tank waste water will be inactivated, or
1. explain why infectious agent are no longer present in tank water, before it is discharged to the sanitary sewer system.
- R **R1592** (replacing 0747) **APPROVED (9-0-0)** Rev: nld

Storage Only

- R **R1602** (replacing 638) **APPROVED (9-0-0)** Rev: mmm

C. Conditional BUAs reviewed by ABSO, Final Approval by BSO: None

BUA No. **0278-03B**

Reviewer: nld

Title: PCB disruption of thyroid hormone action during developmen

BUA No. 0710B	Reviewer: nld
Title: <u>Regulation of calcium signaling in T cells</u>	
BUA No. 0743-02	Reviewer: nld
Title: <u>Isolating a cDNA library from <i>Plasmodium gallinaceum</i></u>	
BUA No. 0747	Reviewer: nld
Title: <u>Role of murine cytomegalovirus in exacerbation of atherosclerosis and graft vs. host</u>	
BUA No. 0951B	Reviewer: nld
Title: <u>Anti-coagulation and sickle cell disease studies</u>	

V. Discussion Items:

1. PB - VA-UCD IBC MOU
2. PB and MMM - BIO BUAs ECPs

VI. Information Items: NONE

VII. IBC Training: NONE

VIII. BSL3 Laboratory Information:

IV. Notifications: NONE

X. Subcommittee Topics: NONE

X. Subcommittee Topics:

End Time: 4:40pm

Institutional BioSafety Committee

Minutes for 03/17/2014

Final

UC Davis
Environmental Health and
Safety
Phone : (530) 752 1493
Fax : (530) 752 4527

Track 3: Subcommittee Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1591		MED:PATHOLOGY & LAB MEDICINE	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title TB serology by multiplex microbead immunoassay

Motion

Reviewer	Biostaff
Review date	April 8, 2014
Comments	PI responded to IBC questions with revision of BUA. BUA received final approval.
Reviewer	IBC
Review date	March 17, 2014
Comments	IBC reviewers requested clarification on use of animal serum.
Reviewer	Biostaff
Review date	February 25, 2014
Comments	1. Assign to nld 2/25, Em Co-PI Qs 3/3, BUA finalized 3/12

Applicable NIH Guidelines

Section	Explanation
None Apply	

Track 3: Subcommittee Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1583	EDUARDO SILVA	BIOMEDICAL ENGINEERING	New	BSL: 2 ABSL:

Action: N/A

Review Stage: IBC

Project Title Engineering Vascular Beds

Motion

Reviewer	Biostaff
Review date	April 11, 2014
Comments	PI addressed IBC concerns and re-submitted BUA for review. Details were added regarding downstream use of viral vector. No sharps (scalpels, needles or glass pipets) are used with the vector.
Reviewer	IBC
Review date	March 17, 2014
Comments	TABLED (No vote taken) IBC reviewers could not approve the BUA because they were unable to form a risk assessment based on the information provided. IBC reviewers request that the following points be addressed in the BUA before it is resubmitted for review: 1. Clarify downstream uses of viral vector 2. Describe any use of sharps (e.g. needles, scalpels or glass pipets) with viral vectors
Reviewer	Biostaff
Review date	February 25, 2014
Comments	1. Assign to mmm 2/25

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3b--lentiviral vector production in human cell culture

Track 2: EH&S Review Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1570	LAURA MARCU	BIOMEDICAL ENGINEERING	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Nuclear imaging and photodynamic therapy studies

Motion

Reviewer	IBC
Review date	March 17, 2014
Comments	APPROVED (9-0-0)

Reviewer	Biostaff
Review date	March 3, 2014
Comments	1. Assign to mmm 3/3

Applicable NIH Guidelines

Section	Explanation
None Apply	

Track 2: EH&S Review Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1576	ROBERT REBHUN	VM: SURG/RAD SCIENCE	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title The relationship between EGFR and hedgehog signaling in colon cancer

Motion

Reviewer	IBC
Review date	March 17, 2014
Comments	APPROVED (9-0-0)
Reviewer	Biostaff
Review date	March 3, 2014
Comments	1. Assign to nld 3/3, 2. Em Qs to PI 3/4, 3. BUA finalized 3/12

Applicable NIH Guidelines

Section	Explanation
None Apply	

Track 1: EH&S Approval Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1602	VALLEY STEWART	MICROBIOLOGY & MOLEC GENETICS	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Storage only: Klebsiella pneumoniae

Motion

Reviewer	IBC
Review date	March 17, 2014
Comments	APPROVED (9-0-0)

Reviewer	IBC
Review date	March 7, 2014
Comments	1. Finalized 3/7 mmm

Applicable NIH Guidelines

Section	Explanation
None Apply	

Track 1: EH&S Approval Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1586		ENVIRONMENTAL SCIENCE & POLICY	New	BSL: 1 ABSL:

Action: Pending

Review Stage: PI Revise

Project Title Effects of a manipulative parasite on population and community dynamics of the California killifish

Motion

Reviewer	IBC
Review date	March 17, 2014
Comments	<p>CONDITIONAL (9-0-0)</p> <p>IBC reviewers request that the following information be clarified in the risk assessment section of the BUA:</p> <p>1. Please describe how infectious agents remaining in tank waste water will be inactivated, or explain why infectious agent are no longer present in tank water, before it is discharged to the sanitary sewer system.</p> <p>The above issues must be addressed before BUA can receive final approval.</p>
Reviewer	Biostaff
Review date	March 3, 2014
Comments	1. Assign to nld 3/3, 2. Em Qs to PI 3/4, 3. Protocol finalized 3/6

Applicable NIH Guidelines

Section	Explanation
None Apply	

Track 1: EH&S Approval Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1566	JEFFREY ROSS-IBARRA	PLANT SCIENCES	New	BSL: 1 ABSL:

Action: Pending

Review Stage: Biostaff

Project Title Functional consequences of evolutionary changes in centromere proteins in maize

Motion

Reviewer	Biostaff
Review date	April 10, 2014
Comments	ABSO confirmed that PI addressed IBC concerns
Reviewer	IBC
Review date	March 17, 2014
Comments	<p>CONDITIONAL (9-0-0)</p> <p>IBC reviewers request that the following information be added to the risk assessment section of the BUA:</p> <ol style="list-style-type: none"> 1. Describe potential consequences if the corn seed were to become mixed with non-GMO corn or accidentally released to the environment (i.e. what is likelihood of volunteer corn sprouting and producing pollen and seed if accidentally spilled in transport? How is GMO seed segregated and distinguished from non-GMO seed in your lab?) 2. Describe pest control and insect exclusion practices used in the greenhouse or indicate why insects would be unlikely risks for pollen flow from experiential corn inside of a greenhouse. <p>The above issues must be addressed before BUA can receive final approval.</p>
Reviewer	Biostaff
Review date	February 25, 2014
Comments	1. Assign to mmm 2/25

Applicable NIH Guidelines

Section	Explanation
IIIE	We will use rDNA-modified plants that are not noxious weeds or that cannot interbreed with noxious weeds in the immediate geographic area, and we will perform experiments involving whole plants and rDNA-modified E.coli that have no recognized potential for rapid and widespread dissemination or for serious detrimental impact on managed or natural ecosystems.

Track 1: EH&S Approval Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1544	PAUL GEPTS	PLANT SCIENCES	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Study the evolution, domestication, and biodiversity of crops at the molecular and whole-plant levels.

Motion

Reviewer	IBC
Review date	March 17, 2014
Comments	APPROVED (9-0-0)

Reviewer	Biostaff
Review date	February 10, 2014
Comments	1. Assign to mmm 2. sent questions to PI 2-13-14

Applicable NIH Guidelines

Section	Explanation
IIIE	IIIE2a- use of Agrobacterium tumefaciens with whole plants
IIIF	IIIF-5- rDNA molecules that consist entirely of DNA from a eukaryotic host including its chloroplasts, mitochondria, or plasmids (but excluding viruses) when propagated only in that host (or closely related strain of the same species). IIIF8 (AppCII) E. coli cloning strains

Track 1: EH&S Approval Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1592		MED: DERMATOLOGY	New	BSL: 1 ABSL: 1

Action: Approved

Review Stage: Completed

Project Title Role of murine cytomegalovirus in exacerbation of atherosclerosis and graft vs. host disease

Motion

Reviewer	IBC
Review date	March 17, 2014
Comments	APPROVED (9-0-0)
Reviewer	Biostaff
Review date	February 26, 2014
Comments	1. Assign to nld 2/26, 1. Em

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1584		MED: PHARMACOLOGY	New	BSL: 2 ABSL: 1

Action: Approved

Review Stage: Completed

Project Title CaMKII and IP3-mediated signaling in cardiac myocytes

Motion

Reviewer	IBC
Review date	March 17, 2014
Comments	APPROVED (8-0-1) PB abst.
Reviewer	Biostaff
Review date	March 3, 2014
Comments	1. Assign to pb 3/3 2. Pre-review (3/8/2014)

Applicable NIH Guidelines

Section	Explanation
IIID	IIID4a (Adeno-, AAV)
IIIF	IIIF8 (App CII, CVII)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1572	MARTA VAN LOAN	NUTRITION	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Mineral and Vitamin Interventions for At-Risk Populations

Motion

Reviewer	IBC
Review date	March 17, 2014
Comments	APPROVED (8-0-1) PB abst.
Reviewer	Biostaff
Review date	February 25, 2014
Comments	1. Assign to pb 2/25/2014 2. Pre-review (3/4/2014) 3. Sent to IBC (3/4/2014)

Applicable NIH Guidelines

Section	Explanation
IIIF	No rDNA work. BUA reviewed for BBP only (human blood)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1568		MED: NEUROLOGY	New	BSL: 2 ABSL: 1

Action: Approved

Review Stage: Completed

Project Title Molecular physiology of CLC chloride channels

Motion

Reviewer	IBC
Review date	March 17, 2014
Comments	APPROVED (8-0-1) PB abst.
Reviewer	Biostaff
Review date	February 25, 2014
Comments	1. Assign to pb 2/25

Applicable NIH Guidelines

Section	Explanation
IIIF	IIIF8 (App CI, CII) BBP only (est. human cells)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1574		MED: DIV OF INTERNAL MED	New	BSL: 2 ABSL: 1

Action: Approved

Review Stage: Completed

Project Title Animal models of Immune disorders and antigen-antibody interactions in cultured cells

Motion

Reviewer	IBC
Review date	March 17, 2014
Comments	APPROVED (8-0-1) PB abst.
Reviewer	Biostaff
Review date	March 3, 2014
Comments	1. Assign to pb 3/3 2. Pre-review (3/8/2013)

Applicable NIH Guidelines

Section	Explanation
IIID	IIID4a (aav)
IIIE	IIIE (E. coli BL21)
IIIF	IIIF8 (App CII)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1580		MED: DIV OF INTERNAL MED	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Development and Validation of Novel Imaging Agents

Motion

Reviewer	IBC
Review date	March 17, 2014
Comments	APPROVED (8-0-1) PB abst.
Reviewer	Biostaff
Review date	February 25, 2014
Comments	1. Assign to pb 2/25 2. Pre-review 3/5/2014

Applicable NIH Guidelines

Section	Explanation
IIID	This project involves the use of BSL-2 cell lines derived from human tissue and recombinant DNA.

Institutional Biosafety Committee, UC Davis
Office of Environmental Health and Safety

MINUTES

April 21 2014 (3-5p)

Hoagland Hall Rm 130

NOTE: Next IBC meeting: 5/19/2014

Start Time: 3:05pm

In attendance:

Philip Barruel	Voting Member, Biosafety Officer, Environmental Health and Safety
Gerhard Bauer	Voting Member, Vice-Chair, IM Div of Hematology/Oncology
Nicole Corley	Voting Member, Campus Veterinary Services
Bruce Draper	Voting Member, Molecular & Cellular Biology
Diane Hoffmann	Voting Member, School of Medicine Sponsored Programs
Johan Leveau	Voting Member, Plant Pathology
Elizabeth Maga	Voting Member, Animal Science
Renee Tsolis	Voting Member, Medical Microbiology & Immunology
Roger Belcourt	Voting Ex-Officio Member, Occupational Health Services
Victor Lukas	Voting Ex-Officio Member, Attending Veterinarian

IBC support staff in attendance:

Malendia Maccree	Associate BioSafety Officer, Environmental Health and Safety
Chips Hoai	Associate BioSafety Officer, Environmental Health and Safety

Excused:

Jill Blackwelder-Parker	Non-Voting Ex-Officio Member, Associate Vice Chancellor, Safety Services
Neil Speth	Non-Voting Ex-Officio Member, UCDMC Employee Health Services
Ioannis Stergiopoulos	Voting Member (alternate), Plant Pathology
Angela Gelli	Voting Member, Chair, Pharmacology
Fred Jacobsen	Voting Member, Public Member
Lyle Najita	Voting Member, Public Member

Guests: None

I. Review of past IBC meeting minutes:

Feb 24, 2014: **APPROVED (9-0-0)**
March 17, 2014: **APPROVED (5-0-4)** *GB, DH, JL, BD abstained*

II. Announcements:

III. Old Business:

R **R1583** (replacing 1006B) **APPROVED (9-0-0)** Rev: mm
(Tabled:3/17/2014)

IV. New Business:

A. Amendments: None

B. BIO BUAs for review see BIO generated agenda:

BSL3

- | | | | |
|---|----------------------------------|-----------------------------------------|---------|
| R | R1616 (replacing 0741-01) | APPROVED (7-0-2) PB and RT abst. | Rev: pb |
| R | R1589 (replacing 0482-02) | APPROVED (10-0-0) | Rev: mm |
| N | R1610 | APPROVED (10-0-0) | Rev: mm |

BSL2

- | | | | |
|---|-------------------------------|-----------------------------|---------|
| R | R1537 (replacing 0050) | CONDITIONAL (10-0-0) | Rev: ch |
|---|-------------------------------|-----------------------------|---------|
- Describe experiments involving zebra fish in the project summary and address the risks of these experiments, or delete all mention of zebra fish from the application if these studies are no longer being performed.
- 1.
- In the Risk Assessment section for Infectious Agents, it is indicated that “work will be carried out with appropriate PPE in a BSC.” Please describe what that “appropriate PPE” consists of.
- 2.
- | | | | |
|---|----------------------------------|----------------------------------|---------|
| R | R1575 (replacing 972B) | APPROVED (9-0-1) PB abst. | Rev: pb |
| R | R1581 (replacing 0819B) | APPROVED (9-0-1) PB abst. | Rev: pb |
| R | R1593 (replacing 0528-02) | APPROVED (10-0-0) | Rev: ch |
| R | R1598 (replacing 0843B) | APPROVED (10-0-0) | Rev: ch |
| R | R1604 (replacing 0961) | APPROVED (10-0-0) | Rev: pb |
| R | R1613 (replacing 0611) | CONDITIONAL (10-0-0) | Rev: ch |
- Describe where the Murine Norovirus was obtained. Will you be growing MNV in the laboratory? Please describe this in the Experimental Procedures section of the risk assessment.
- 1.
 - 2.
 - 3.
 - 4.
- Please address whether a functional toxin will be expressed during the recombinant DNA experiments in the risk assessment section.
- | | | | |
|---|-------------------------------|----------------------------|---------|
| R | R1621 (replacing 0847) | APPROVED (9-0-0) | Rev: ch |
| N | R1622 | CONDITIONAL (9-0-0) | Rev: ch |
1. Please amend the IACUC protocol to reflect the HSV experiments described in the BUA prior to commencing this work, and to include this infectious disease model.
The Committee is concerned the HSV infection in mice may follow the human model of HSV and can become reactivated after latency. The risk assessment appears to be based on assumptions that HSV will not be shed by the animal. Please provide published documentation in the attachments section that support this assumption. If documentation cannot be provided, please amend the risk assessment section of the application to reflect that all animals will be treated as if they are potentially infectious.
 - a. If documentation cannot be provided, please indicate how equipment and wastes will be disinfected or treated in the risk assessment section of the BUA.
 - b. If documentation cannot be provided, please update the IACUC RLSS to reflect how animals should be handled.
 - 2.

3. The risk assessment indicates hyperthermic stress can reactivate HSV in mice. In the risk assessment section, please indicate how the animals will be tested to ensure this has not occurred during transportation of animals or during exertional behavioral assessment.
4. The risk assessment states randomly selected mice will be selected for testing to screen for infectious HSV prior to shipment. The Committee would like to know why all animals are not tested for infectious HSV prior to shipment. Animals not tested may contain infectious HSV and inadvertently be shipped. Please indicate what method is used to determine they are not shedding or infectious.
5. The Committee would like to know if there are tests that can be performed in order to ensure that HSV is not shed in saliva, urine or feces that will contaminate bedding.
6. The study locations include facilities used for animals from multiple studies. The Committee has expressed concerns regarding the containment of HSV. Please address the risks of HSV to other animals or personnel in the facility.

N **R1623** **APPROVED (9-0-0)** Rev: mm

BBP only

R **R1601** (replacing 0976B) **APPROVED (8-0-1) PB abst.** Rev: pb

N **R1595** **APPROVED (9-0-0)** Rev: mm

N **R1627** **APPROVED (8-0-1) PB abst.** Rev: ch

BSL1

R **R1588** (replacing 0491) **APPROVED (9-0-0)** Rev: mmm

N **R1638** **APPROVED (9-0-0)** Rev: mmm

Storage Only: NONE

Exempt Protocols: NONE

C. Conditional BUAs reviewed by ABSO, Final Approval by BSO: None

R **R1591** (replacing 0347-03) [REDACTED] Reviewer: nld
Conditional Approval Date: 3/17/2014

N **R1566** Ross-Ibarra, Jeffrey Reviewer: mm
Conditional Approval Date: 3/17/2014

N **R1529** Schmitt, Joanna Reviewer: mm
Conditional Approval Date: 2/24/2014

R **R1536** (replacing 0915-02B) Li, Tianhong Reviewer: pb
Conditional Approval Date: 2/24/2014

R **R1538** (replacing 0840) [REDACTED] Reviewer: pb
Conditional Approval Date: 2/24/2014

R **R1556** (replacing 0960) David, Shiela Reviewer: pb

Conditional Approval Date: 2/24/2014

R **R1560** (replacing 0838) [REDACTED]
Conditional Approval Date: 2/24/2014

Reviewer: pb

R **R1562** (replacing 0834) Jiang, Cai-Zhong
Conditional Approval Date: 2/24/2014

Reviewer: mm

Amend **0978(A)** [REDACTED]
Title: The effects of altered cellular zinc homeostasis on body weight regulation, diabetes development, and cancer risk

Reviewer: pb

Amendment to add: Lentiviral particles expressing shRNA used to transduce rodent cell lines

Exp date: 07/18/2014

Conditional Approval Date: 2/24/2014

D. Terminated BUAs:

BUA No. **0591B** Wilson, Barry
Title: Cholinesterase, neurotoxic esterase and other enzymes of human tissue

Reviewer: mm

V. Discussion Items:

1. Vote to approve nomination of new IBC non-affiliated member - Dr. William Buhles (Philip)
APPROVED (9-0-0)
2. Vote to approve nomination of new VA-affiliated UCD faculty IBC member Sue Bodine.
APPROVED (9-0-0)

VI. Information Items:

1. CAES Faculty (D. Ullman and A. Dandekar) will be meeting with the Dean Hillard to request support for the BQMS program (USDA-APHIS-BRS compliance). (Malendia)

VII. IBC Training: NONE

VIII. BSL3 Laboratory Information:

IV. Notifications: NONE

X. Subcommittee Topics: NONE

X. Subcommittee Topics:

End Time: 4:56pm

Institutional BioSafety Committee

Minutes for 04/21/2014

Final

UC Davis

Environmental Health and
Safety

Phone : (530) 752 1493

Fax : (530) 752 4527

Track 3: Subcommittee Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1583	EDUARDO SILVA	BIOMEDICAL ENGINEERING	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Engineering Vascular Beds

Motion

Reviewer	IBC
Review date	April 21, 2014
Comments	APPROVED (9-0-0)
Reviewer	Biostaff
Review date	April 11, 2014
Comments	PI addressed IBC concerns and re-submitted BUA for review. Details were added regarding downstream use of viral vector. No sharps (scalpels, needles or glass pipets) are used with the vector.
Reviewer	IBC
Review date	March 17, 2014
Comments	TABLED (No vote taken) IBC reviewers could not approve the BUA because they were unable to form a risk assessment based on the information provided. IBC reviewers request that the following points be addressed in the BUA before it is resubmitted for review: 1. Clarify downstream uses of viral vector 2. Describe any use of sharps (e.g. needles, scalpels or glass pipets) with viral vectors
Reviewer	Biostaff
Review date	February 25, 2014
Comments	1. Assign to mmm 2/25

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3b--lentiviral vector production in human cell culture

Track 3: Subcommittee Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1616		MED:MEDICAL MICROBIOLOGY & IMM	New	BSL: 3 ABSL: 3

Action: N/A

Review Stage: IBC

Project Title Mechanisms of infection by intracellular bacterial pathogens

Motion

Reviewer	Biostaff
Review date	April 12, 2014
Comments	Pre-review (4/12/2-14) (PB).

Applicable NIH Guidelines

Section	Explanation
IIID	II-D-1-a Introduction of recombinant or synthetic nucleic acids into Risk Group 2 (RG-2) agents. III-D-1-b Introduction of recombinant or synthetic nucleic acids into Risk Group 3 (RG-3) agents. III-D-2-a Experiments in which DNA from RG- 2, RG- 3 agents, or RG-4 agents is transferred into nonpathogenic prokaryotes or lower eukaryotes.
IIIE	IIIE
IIIF	IIIF8 App CI, CII

Track 1: EH&S Approval Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1589	ROBERT GILBERTSON	PLANT PATHOLOGY	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Investigation into the biology, evolution, genetics and management of geminiviruses and tospoviruses

Motion

Reviewer	Biostaff
Review date	
Comments	Assigned to MM
Reviewer	IBC
Review date	April 21, 2014
Comments	APPROVED (10-0-0)

Applicable NIH Guidelines

Section	Explanation
IIID	IIID5a -- Use of exotic infectious agents (viral genomes) with recognized potential for serious detrimental impact on managed or natural ecosystems with whole plants (BL3P)
IIIE	IIIE2a -- Use of Agrobacterium with whole plants IIIE2b(2) -- Plants in which the introduced DNA represents the complete genome of a non-exotic infectious agent IIIE -- Expression of proteins in E. coli BL1
IIIF	IIIF-8 (AppCI, CII) -- sequencing of PCR products, use of E. coli Dh5a

Track 1: EH&S Approval Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1610	KRIS GODFREY	ENTOMOLOGY	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Transmission of Citrus Leprosis Virus by Brevipalpus mites

Motion

Reviewer	IBC
Review date	April 21, 2014
Comments	APPROVED (10-0-0)

Reviewer	Biostaff
Review date	March 19, 2014
Comments	Assigned to MM

Applicable NIH Guidelines

Section	Explanation
None Apply	

Institutional Biosafety Committee, UC Davis
Office of Environmental Health and Safety

MINUTES

May 19 2014 (3-5p)

Hoagland Hall Rm 130

NOTE: Next IBC meeting: 6/16/2014

Start Time: 3:02pm

In attendance:

Angela Gelli	Voting Member, Chair, Pharmacology
Philip Barruel	Voting Member, Biosafety Officer, Environmental Health and Safety
Gerhard Bauer	Voting Member, Vice-Chair, IM Div of Hematology/Oncology
Sue Bodine	Voting Member, Neurobiology, Physiology, and Behavior
Nicole Corley	Voting Member, Campus Veterinary Services
Fred Jacobsen	Voting Member, Public Member
Johan Leveau	Voting Member, Plant Pathology
Elizabeth Maga	Voting Member, Animal Science
Roger Belcourt	Voting Ex-Officio Member, Occupational Health Services
Victor Lukas	Voting Ex-Officio Member, Attending Veterinarian

IBC support staff in attendance:

Malendia Maccree	Associate BioSafety Officer, Environmental Health and Safety
Chips Hoai	Associate BioSafety Officer, Environmental Health and Safety

Excused:

Jill Blackwelder-Parker	Non-Voting Ex-Officio Member, Associate Vice Chancellor, Safety Services
Neil Speth	Non-Voting Ex-Officio Member, UCDMC Employee Health Services
Ioannis Stergiopoulos	Voting Member (alternate), Plant Pathology
Bruce Draper	Voting Member, Molecular & Cellular Biology
Diane Hoffmann	Voting Member, School of Medicine Sponsored Programs
Renee Tsolis	Voting Member, Medical Microbiology & Immunology
Lyle Najita	Voting Member, Public Member

Guests: Brain Buckley (UC Davis Police Department)

I. Review of past IBC meeting minutes:

April 21, 2014 **APPROVED (9-0-1) SB abst.**

II. Announcements:

III. Old Business: None

III. New Business:

BSL2

R	R1579 (replacing 841)	APPROVED (9-0-1) SB abst.	Rev: ch
R	R1607 (replacing 746)	APPROVED (9-0-1) SB abst.	Rev: mm

R	R1612 (replacing 966)	APPROVED (9-0-1) SB abst.	Rev: ch
R	R1626 (replacing 725)	APPROVED (9-0-1) SB abst.	Rev: ch
R	R1639 (replacing 642)	APPROVED (8-0-2) PB, SB abst.	Rev: pb
R	R1640 (replacing 767)	APPROVED (9-0-1) SB abst.	Rev: mm
R	R1642 (replacing 694)	APPROVED (8-0-2) PB, SB abst.	Rev: pb
R	R1651 (replacing 576)	APPROVED (8-0-2) PB, SB abst.	Rev: pb
R	R1653 (replacing 844)	APPROVED (9-0-1) SB abst.	Rev: mm

BBP only

R	R1519 (replacing 744)	APPROVED (9-0-1) SB abst.	Rev: ch
N	R1554	APPROVED (9-0-1) SB abst.	Rev: ch
N	R1630	APPROVED (9-0-1) SB abst.	Rev: ch

BSL1

R	R1597 (replacing 964)	CONDITIONAL (9-0-1) SB abst.	Rev: mm
---	------------------------------	-------------------------------------	---------

1. Section 4, biological materials--plants: sunflower plants are mentioned but not listed as a host on the BUA.
2. Section 4, biological materials—plant virus/viral vector and nucleic acids: please clarify what percentage of the curtovirus genome and/or which viral genes will be transferred to plant hosts.
3. Section 7, experimental procedures: please provide more detail regarding the work conducted with viruliferous leafhoppers, such as the end use of the infected leafhoppers and whether these insects are used to vector virus to plants.

R	R1603 (replacing 940)	APPROVED (9-0-1) SB abst.	Rev: ch
---	------------------------------	----------------------------------	---------

Storage Only: NONE

Exempt Protocols:

R	R1650 (replacing 946)		Rev: ch
---	------------------------------	--	---------

B. Amendments (see BIO or download documents from SmartSite):

R1518 (BIO amendment)	APPROVED (8-0-2) PB, SB abst.	Rev: pb
R1591 (BIO amendment)	APPROVED (9-0-1) SB abst.	Rev: mm
814 (A) (SmartSite)	APPROVED (9-0-1) SB abst.	Rev: mm

C. Conditional BUAs reviewed by ABSO, Final Approval by BSO:

R	R1537	Rev: ch
	<i>Conditional Approval Date: 5/1/2014</i>	
R	R1613	Rev: ch
	<i>Conditional Approval Date: 4/28/2014</i>	
R	R1622	Rev: ch
	<i>Conditional Approval Date: 5/15/2014</i>	

D. Terminated BUAs:

0051-04	Rev: mm
----------------	---------

Photobioreactor studies of sugar production by cyanobacteria

0687

Rev: mm

Regulation of gene expression by microRNAs in chondrocytes

0785-03

Rev: mm

A non-human primate model of rhinovirus infection

V. Discussion Items:

VI. Information Items:

1. ATD training
2. Guest, Brian Buckley (UCDPD), to discuss campus lab security policy.

VII. IBC Training: NONE

VIII. BSL3 Laboratory Information:

1. [REDACTED] reverification

IV. Notifications: NONE

X. Subcommittee Topics: NONE

End Time: 5:04pm

Institutional BioSafety Committee

Minutes for 05/19/2014

Final

UC Davis

Environmental Health and
Safety

Phone : (530) 752 1493

Fax : (530) 752 4527

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1613	STEFAN WUERTZ	CIVIL & ENVIRONMENTAL ENGR	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Management of pathogens in stormwater run off and bacterial diversity in wastewater reactors

Motion

Reviewer	Biostaff
Review date	April 28, 2014
Comments	PI addressed all issues identified by the Committee.
Reviewer	IBC
Review date	April 21, 2014
Comments	<p>CONDITIONAL (10-0-0)</p> <p>The Institutional Biosafety Committee CONDITIONALLY APPROVED your Biological Use Authorization and requests that you submit a revised application that addresses the following points:</p> <ol style="list-style-type: none"> 1. Describe where the Murine Norovirus was obtained. Will you be growing MNV in the laboratory? Please describe this in the Experimental Procedures section of the risk assessment. 2. Please clarify how 110 L of waste water will be disposed. 3. Please describe how the 110 L and 7 L stainless steel tanks will be disinfected. 4. Please address whether a functional toxin will be expressed during the recombinant DNA experiments in the risk assessment section.
Reviewer	Biostaff
Review date	April 9, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-2-a Experiments in which DNA from RG- 2, RG- 3 agents, or RG-4 agents is transferred into nonpathogenic prokaryotes or lower eukaryotes.

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1537	JODI NUNNARI	MOLECULAR & CELLULAR BIO	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Mitochondrial dynamics in mammalian systems

Motion

Reviewer	Biostaff
Review date	May 1, 2014
Comments	PI addressed all issues identified by the Committee.
Reviewer	IBC
Review date	April 21, 2014
Comments	<p>CONDITIONAL (10-0-0)</p> <p>The Institutional Biosafety Committee CONDITIONALLY APPROVED your Biological Use Authorization and requests that you submit a revised application that addresses the following points:</p> <p>-Describe experiments involving zebra fish in the project summary and address the risks of these experiments, or delete all mention of zebra fish from the application if these studies are no longer being performed.</p> <p>-In the Risk Assessment section for Infectious Agents, it is indicated that work will be carried out with appropriate PPE in a BSC. Please describe what that appropriate PPE consists of.</p>
Reviewer	Biostaff
Review date	March 27, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIIE	Experiments involving the formation of recombinant or synthetic nucleic acid molecules containing no more than 2/3 of the genome of any eukaryotic virus (all viruses from a single Family being considered identical) may be propagated and maintained in cells in tissue culture using BSL1 for MMLV in MEF cell lines

Status of BUAs Pending from Previous Meetings - Completed

Section	Explanation
IIIF	III-F-8 recombinant or synthetic nucleic acid molecules that do not present a significant risk to health or the environment for work with plasmids in human and mouse cells

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1591		MED:PATHOLOGY & LAB MEDICINE	Amend	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title TB serology by multiplex microbead immunoassay

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	APPROVED (9-0-1) SB abst.
Reviewer	Biostaff
Review date	April 29, 2014
Comments	Assigned to mmm

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1640		MED: BIOCHEM & MOLECULAR MED	New	BSL: 2 ABSL: 1

Action: Approved

Review Stage: Completed

Project Title Genome Engineering in Mammalian Systems

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	APPROVED (9-0-1) SB abst.
Reviewer	Biostaff
Review date	May 1, 2014
Comments	assigned to mmm

Applicable NIH Guidelines

Section	Explanation
IIID	Section III-D-4-a. Recombinant or synthetic nucleic acid molecules, or DNA or RNA molecules derived therefrom, from any source except for greater than two-thirds of eukaryotic viral genome may be transferred to any non-human vertebrate or any invertebrate organism and propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study.
IIIE	Section III-E-1. Recombinant or synthetic nucleic acid molecules containing no more than two-thirds of the genome of any eukaryotic virus may be propagated and maintained in cells in tissue culture using BL1 containment.

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1612	FRANK CHUANG	MED: BIOCHEM & MOLECULAR MED	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Investigating mechanisms of HIV transfer using advanced fluorescence microscopy

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	APPROVED (9-0-1)

Reviewer	Biostaff
Review date	May 2, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-1-a, for adding iGFP and iCherry to HIV

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1630	MAGGIE KUHN	UCDMC CLINICAL FELLOWS	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Skeletal muscle tissue harvest during total for mesenchymal stem cell acquisition.

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	APPROVED (9-0-1)

Reviewer	Biostaff
Review date	May 9, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1518		BIOMEDICAL ENGINEERING	Amend	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title In vitro and in vivo evaluation and imaging of delivery vehicle targeting, accumulation, biodistribution, drug release and therapeutic efficacy in tumor cancer models and endothelial cells for various disease models

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	APPROVED (8-0-2) PB, SB abst.
Reviewer	Biostaff
Review date	May 13, 2014
Comments	1. Pre-review, PB (4/13/2014)

Applicable NIH Guidelines

Section	Explanation
IIID	NIH Guidelines III-D-4a
IIIF	IIIF8 (App CI)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1622		MED: SURGERY	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Behavioral assessment of mice infected with HSV-1 and treated with Acyclovir or Acyclovir in combination with IVIG

Motion

Reviewer	Biostaff
Review date	May 15, 2014
Comments	PI addressed all issues identified by the Committee.

Status of BUAs Pending from Previous Meetings - Completed

Reviewer	IBC
Review date	April 21, 2014
Comments	<p>CONDITIONAL (9-0-0)</p> <p>The Institutional Biosafety Committee CONDITIONALLY APPROVED your Biological Use Authorization and requests that you submit a revised application that addresses the following points:</p> <ol style="list-style-type: none"> 1. Please amend the IACUC protocol to reflect the HSV experiments described in the BUA prior to commencing this work, and to include this infectious disease model. 2. The Committee is concerned the HSV infection in mice may follow the human model of HSV and can become reactivated after latency. The risk assessment appears to be based on assumptions that HSV will not be shed by the animal. Please provide published documentation in the attachments section that support this assumption. If documentation cannot be provided, please amend the risk assessment section of the application to reflect that all animals will be treated as if they are potentially infectious. If documentation cannot be provided, please indicate how equipment and wastes will be disinfected or treated in the risk assessment section of the BUA. If documentation cannot be provided, please update the IACUC RLSS to reflect how animals should be handled. 3. The risk assessment indicates hyperthermic stress can reactivate HSV in mice. In the risk assessment section, please indicate how the animals will be tested to ensure this has not occurred during transportation of animals or during exertional behavioral assessment. 4. The risk assessment states randomly selected mice will be selected for testing to screen for infectious HSV prior to shipment. The Committee would like to know why all animals are not tested for infectious HSV prior to shipment. Animals not tested may contain infectious HSV and inadvertently be shipped. Please indicate what method is used to determine they are not shedding or infectious. 5. The Committee would like to know if there are tests that can be performed in order to ensure that HSV is not shed in saliva, urine or feces that will contaminate bedding. 6. The study locations include facilities used for animals from multiple studies. The Committee has expressed concerns regarding the containment of HSV. Please address the risks of HSV to other animals or personnel in the facility.
Reviewer	Biostaff
Review date	March 31, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1554	ANGELA ZIVKOVIC	NUTRITION	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Interaction of diet and the gut microbiome in preventing chronic inflammatory diseases

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	APPROVED (9-0-1)

Reviewer	Biostaff
Review date	April 21, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1626	BARBARA SHACKLETT	MED:MEDICAL MICROBIOLOGY & IMM	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Immune responses to HIV-1 in mucosal tissues

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	APPROVED (9-0-1)
Reviewer	Biostaff
Review date	April 15, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1651	JANINE LASALLE	MED:MEDICAL MICROBIOLOGY & IMM	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Noncoding RNAs at the heart of the Prader-Willi locus

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	APPROVED (8-0-2) PB, SB abst.
Reviewer	Biostaff
Review date	May 14, 2014
Comments	1. Pre-review (PB)

Applicable NIH Guidelines

Section	Explanation
IIIE	IIIE1 (aav)
IIIF	IIIF8 (App CII)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1607		VM: MEDICINE & EPIDEMIOLOGY	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Community ecology of pathogens

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	APPROVED (9-0-1) SB abst.
Reviewer	Biostaff
Review date	April 22, 2014
Comments	assigned to mmm

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1639	MARK ZERN	MED: DIV OF INTERNAL MED	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Gene therapy, molecular therapy and cell-based therapy for liver diseases

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	APPROVED (8-0-2) PB, SB abst.

Reviewer	Biostaff
Review date	May 13, 2014
Comments	1. Pre-review (PB)

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3b (lenti), IIID3a (adeno)
IIIF	IIIF8 (CII)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1603	DAVID GOODIN	CHEMISTRY	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Novel substrate oxidation by metalloenzyme engineering

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	APPROVED (9-0-1)

Reviewer	Biostaff
Review date	April 16, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIIE	III-E-1 for use of rDNA plasmids in BL strains of E. coli
IIIF	III-F-8 recombinant or synthetic nucleic acid molecules that do not present a significant risk to health or the environment

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1597	ALLEN VAN DEYNZE	PLANT SCIENCES	New	BSL: 1 ABSL:

Action: Pending

Review Stage: PI Revise

Project Title Crop Improvement and Disease Resistance

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	<p>CONDITIONAL (9-0-1) SB abst.</p> <p>IBC reviewers request that the following points be addressed in revision of your BUA:</p> <ol style="list-style-type: none"> 1. Section 7, experimental procedures: please provide more detail regarding the work conducted with viruliferous leafhoppers, such as the end use of the infected leafhoppers and whether these insects are used to vector virus to plants. 2. Section 4, biological materials--plants: if sunflower plants will be used in this work, please add this plant host to the BUA. 3. Section 4, biological materialsplant virus/viral vector and nucleic acids: please clarify what percentage of the curtovirus genome and/or which viral genes will be transferred to plant hosts. <p>The above points must be addressed before the BUA can receive final approval.</p>
Reviewer	Biostaff
Review date	April 28, 2014
Comments	assigned to mmm

Applicable NIH Guidelines

Section	Explanation
IIIE	IIIE2a - Use of Agrobacterium for transgenic plant production and transient expression. IIIE2b(2) - plants in which the introduced DNA represents the complete genome of a non-exotic infectious agent (curtovirus).
IIIF	IIIF8 (App CII) - use of E. coli K 12 strains for routine cloning.

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1579		MED:PSYCHIATRY & BEHAV SCI	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Proliferation and Migration in the Developing Neocortex

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	APPROVED (9-0-1)
Reviewer	Biostaff
Review date	May 2, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3b (lenti) IIID3e (retro) IIID4a (animals)
IIIE	IIIE1 (non-exempt E. coli)
IIIF	IIIF8 App CI (virus in tc), App CII (E. coli K12)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1650		PSYCHOLOGY	New	BSL: 1 ABSL: 1

Action: Approved

Review Stage: Completed

Project Title Effects of stress on brain and behavior

Motion

Reviewer	Biostaff
Review date	May 19, 2014
Comments	Biosafety Staff has confirmed that the research described in this BUA is exempt from NIH Guidelines
Reviewer	Biostaff
Review date	April 29, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIIF	III-F-1 for using synthetic nucleic acids that: (1) can neither replicate nor generate nucleic acids that can replicate in any living cell (oligonucleotides in mice) are not designed to integrate into DNA, and (3) do not produce a toxin that is lethal for vertebrates at an LD50 of less than 100 nanograms per kilogram body weight.

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1653		ANIMAL SCIENCE	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Analysis of hormonally responsive promoter sequences

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	APPROVED (9-0-1) SB abst.
Reviewer	Biostaff
Review date	May 16, 2014
Comments	assigned to MMM

Applicable NIH Guidelines

Section	Explanation
IIID	IIID4a (lentiviral vector production and use in whole animals), IIID3b (lentiviral vector production and use in cell culture systems)
IIIE	IIIE- plasmid-driven expression in cells and bacteria
IIIF	IIIF8 (app CVII, CVIII) - acquisition and use of transgenic mice

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1642		ANIMAL SCIENCE	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Isolation of bacteria associated with bovine respiratory disease (BRD)

Motion

Reviewer	IBC
Review date	May 19, 2014
Comments	APPROVED (8-0-2) PB, SB abst.
Reviewer	Biostaff
Review date	May 14, 2014
Comments	1. Pre-review (PB)

Applicable NIH Guidelines

Section	Explanation
None Apply	

Institutional Biosafety Committee, UC Davis
Office of Environmental Health and Safety

MINUTES

June 16, 2014

Hoagland Hall Rm 130

NOTE: Next IBC meeting: 7/11/2014

Start Time: 3:05pm

In attendance:

Angela Gelli	Voting Member, Chair, Pharmacology
Bruce Draper	Voting Member, Molecular & Cellular Biology
Diane Hoffmann	Voting Member, School of Medicine Sponsored Programs
Elizabeth Maga	Voting Member, Animal Science
Fred Jacobsen	Voting Member, Public Member
Gerhard Bauer	Voting Member, Vice-Chair, IM Div of Hematology/Oncology
Johan Leveau	Voting Member, Plant Pathology
Nicole Corley	Voting Member, Campus Veterinary Services
Philip Barruel	Voting Member, Biosafety Officer, Environmental Health and Safety
Renee Tsois	Voting Member, Medical Microbiology & Immunology
Sue Bodine	Voting Member, Neurobiology, Physiology, and Behavior
Victor Lukas	Voting Ex-Officio Member, Attending Veterinarian
William Buhles	Voting Member, Public Member

IBC support staff in attendance:

Malendia Maccree	Associate BioSafety Officer, Environmental Health and Safety
Chips Hoai	Associate BioSafety Officer, Environmental Health and Safety

Excused:

Jill Blackwelder-Parker	Non-Voting Ex-Officio Member, Associate Vice Chancellor, Safety Services
Neil Speth	Non-Voting Ex-Officio Member, UCDMC Employee Health Services
Ioannis Stergiopoulos	Voting Member (alternate), Plant Pathology
Lyle Najita	Voting Member, Public Member
Roger Belcourt	Voting Ex-Officio Member, Occupational Health Services

Guests:

I. Review of past IBC meeting minutes:

May 19, 2014 ***APPROVED (11-0-2) SB and WB abst.***

II. Announcements:

III. Old Business: None

IV. New Business:

BSL2

R R1606 (replacing 653)	<i>APPROVED (9-0-4) PB, SB, and WB abs</i>	Rev: pb
R R1628 (replacing 649)	<i>CONDITIONAL (11-0-2) SB and WB a</i>	Rev: ch

R **R1656** (replacing 849-01) *APPROVED (11-0-2) SB and WB abst.* Rev: ch
R **R1664** *APPROVED (11-0-2) SB and WB abst.* Rev: ch
R **R1665** (replacing 975) *APPROVED (11-0-2) SB and WB abst.* Rev: ch

BSL1

R **R1641** *APPROVED (11-0-2) SB and WB abst.* Rev: mm
N **R1643** (replacing 970) *APPROVED (11-0-2) SB and WB abst.* Rev: mm
N **R1667** (replacing 861) *APPROVED (11-0-2) SB and WB abst.* Rev: mm

Storage Only: NONE

Exempt Protocols: None

B. Amendments (download documents from SmartSite):

578-02(A) (SmartSite) Reviewer: mm
APPROVED (11-0-2) SB and WB abst.
1044 (C) (SmartSite) Reviewer: mm
APPROVED (11-0-2) SB and WB abst.

C. Conditional BUAs reviewed by ABSO, Final Approval by BSO: None

D. Terminated BUAs: None

V. Discussion Items:

1. ATD training will soon be available online (Philip)
2. ABSL classification for work with viral vectors in animals – Biosafety office requests IBC guidance in setting policy for the criteria used to determine ABSL for housing of animals which have been treated with viral vectors, with specific attention to requirements for holding at ABSL2 after injections of viral vectors. The topic was posed for discussion in July meeting and IBC members were sent a scientific publication via email as background information to inform their discussion. (Philip)
3. PPE recommendation for Microbiology classes - Biosafety officer would like to request that reusable lab coats be autoclaved or otherwise disinfected before they are taken home by student at end of class. IBC members agreed with the biosafety officer's concerns and found the request to be reasonable and consistent with standard microbiological safety practices. (Philip)
4. Training requirements for BBP

VI. Information Items:

1. [REDACTED] (Malendia)
2. VMTH Coxiella exposure

VII. IBC Training: None

VIII. BSL3 Laboratory Information: None

IX. Notifications:

- Annual review of Dr. Asmuth's Human Gene Transfer clinical trial (BUA#C1468) has been completed. Study is still in progress. No SAE related to the study drug or other concerns to report. Renewed protocol is available for review by IBC members. Any questions regarding the study should be directed to the Biosafety Office. (Malendia)
- 1.

X. Subcommittee Topics: None

End Time: 4:30 p.m.

Institutional BioSafety Committee

Minutes for 06/16/2014

Final

UC Davis

Environmental Health and
Safety

Phone : (530) 752 1493

Fax : (530) 752 4527

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1628	ANNE USREY	MED: NEUROLOGY	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Cellular and molecular mechanisms of synapse formation and elimination

Motion

Reviewer	Biostaff
Review date	June 25, 2014
Comments	PI addressed all issues identified by the Committee.
Reviewer	IBC
Review date	June 16, 2014
Comments	<p>CONDITIONAL (11-0-2)</p> <p>The Institutional Biosafety Committee CONDITIONALLY APPROVED your Biological Use Authorization and requests that you submit a revised application that addresses the following points:</p> <ol style="list-style-type: none"> 1. The Committee expressed concern regarding the use of a laminar flow hood for transfections not involving lentivirus or human-derived cell lines. The Committee was uncomfortable with the added risk of having recombinant DNA materials blown directly at the user when working in a laminar flow hood. If a cleaner environment is required, the IBC recommends considering alternatives, such as using a certified biological safety cabinet or plexiglass box for these experiments. 2. The Committee would like to know if non-human primate materials will be used in the laminar flow hood. The risk assessment does not expressly state that these materials will not be used. 3. The Committee would like clarification on how the non-human primate materials will be fixed prior to working on the bench top. 4. The Committee would like the following sentence regarding lentivirus added to the risk assessment, The risk of insertional mutagenesis is possible. 5. In the risk assessment for infectious agents, the Committee would like the word proliferating removed from the second paragraph. 6. In the risk assessment for recombinant DNA methods, the Committee would like the words filter sterilized through be changed to filtered through and amend GFP-transfected cells and LacZ-transfected cells to GFP-transduced cells and LacZ-transduced cells, respectively. 7. In the risk assessment for research materials, the Committee would like no known be changed to unknown and remove the word nonetheless.

Status of BUAs Pending from Previous Meetings - Completed

Reviewer	Biostaff
Review date	May 23, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-1-a, III-D-2-a - lentivirus work
IIIF	III-F-8 (appendix C-II) - plasmids in K12 strains of E. coli

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1664		MED: BIOCHEM & MOLECULAR MED	New	BSL: 2 ABSL: 1

Action: Approved

Review Stage: Completed

Project Title Characterizing Optical Biosensors in Acute Brain Slices

Motion

Reviewer	IBC
Review date	June 16, 2014
Comments	APPROVED (11-0-2)

Reviewer	Biostaff
Review date	May 23, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-4-a: AAV in whole animals
IIIE	III-E-1: Viral production requires plasmid engineering which contains less than two thirds of a eukaryotic virus.
IIIF	Viral production plasmids fit the description of III-F-8 Appendix C-II.

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1665		MED: DIV OF INTERNAL MED	New	BSL: 2 ABSL: 1

Action: Approved

Review Stage: Completed

Project Title The role of IL-23/IL-17 axis in immune bone loss

Motion

Reviewer	IBC
Review date	June 16, 2014
Comments	APPROVED (11-0-2)
Reviewer	Biostaff
Review date	May 28, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-4-a for plasmids in mice
IIIF	due to III-F-1 synthetic nucleic acids that: (1) can neither replicate nor generate nucleic acids as the minicircle DNA that are injected in mice do not carry any bacterial backbone and lack the origin of replication.

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1643	TAKAO KASUGA	PLANT PATHOLOGY	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Genomic and transcriptomic analysis of pathogenic Phytophthora species in California

Motion

Reviewer	IBC
Review date	June 16, 2014
Comments	APPROVED (11-0-2) SB and WB abst.

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1641	CLARE CASTEEL	PLANT PATHOLOGY	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title The impact of plant viruses on aphid-plant interactions

Motion

Reviewer	IBC
Review date	June 16, 2014
Comments	APPROVED (11-0-2) SB and WB abst.

Applicable NIH Guidelines

Section	Explanation
IIIE	<p>IIIE. use of BL21 E. coli for expression of proteins</p> <p>IIIE-2-a. use of Agrobacterium with plants</p> <p>III-E-2-b-(2). Plants in which the introduced DNA represents the complete genome of a non-exotic infectious agent.</p> <p>III-E-2-b-(4). Plants associated with recombinant or synthetic nucleic acid molecule-modified exotic microorganisms that have no recognized potential for serious detrimental impact on managed or natural ecosystems.</p> <p>III-E-2-b-(5) - Experiments with arthropods or small animals with recombinant or synthetic nucleic acid molecule-modified microorganisms associated with them, if the recombinant or synthetic nucleic acid molecule-modified microorganisms have no recognized potential for serious detrimental impact on managed or natural ecosystems.</p>
IIIF	IIIF8 (app CII) - Use of E. coli K12 strains

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1667	LI TIAN	PLANT SCIENCES	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Terpenoids and polyphenols: Understanding and manipulating two major phytonutrient biosynthetic pathways in plants

Motion

Reviewer	IBC
Review date	June 16, 2014
Comments	APPROVED (11-0-2) SB and WB abst.

Applicable NIH Guidelines

Section	Explanation
IIIE	IIIE2a - use of Agrobacterium species with plants. IIIE - use of rDNA in E. coli BL21
IIIF	IIIF8 (app CII, CIII) - use of rDNA on E. Coli K12 and S. cerevisiae

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1606		VM: PATHOLOGY MICRO & IMMUN	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Cultivation, characterization and immunopathogenesis of protozoal parasites affecting animals and humans

Motion

Reviewer	IBC
Review date	June 16, 2014
Comments	Approved (9-0-4)
Reviewer	Biostaff
Review date	June 9, 2014
Comments	PB pre-review (6/9/2014).

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1656		VM: PATHOLOGY MICRO & IMMUN	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Mutations in small ruminant lentivirus promoters determine disease outcome

Motion

Reviewer	IBC
Review date	June 16, 2014
Comments	APPROVED (11-0-2)
Reviewer	Biostaff
Review date	May 12, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIIE	III-E-1: viral promoters will be cloned into expression vectors (pBLUE TOPO) to determine the functionality of the promoter in vitro (pBLUE TOPO reporter gene is beta galactosidase).

Institutional Biosafety Committee, UC Davis
Office of Environmental Health and Safety

MINUTES

July 11, 2014

Conference call

NOTE: Next IBC meeting: 7/21/2014

Start Time: 9:02 am

In attendance:

Angela Gelli	Voting Member, Chair, Pharmacology
Bruce Draper	Voting Member, Molecular & Cellular Biology
Elizabeth Maga	Voting Member, Animal Science
Gerhard Bauer	Voting Member, Vice-Chair, IM Div of Hematology/Oncology
Lyle Najita	Voting Member, Public Member
Nicole Corley	Voting Member, Campus Veterinary Services
Philip Barruel	Voting Member, Biosafety Officer, Environmental Health and Safety
Renee Tsolis	Voting Member, Medical Microbiology & Immunology

IBC support staff in attendance:

Malendia Maccree	Associate BioSafety Officer, Environmental Health and Safety
------------------	--------------------------------------------------------------

Excused:

Chips Hoai	Associate BioSafety Officer, Environmental Health and Safety
Sue Bodine	Voting Member, Neurobiology, Physiology, and Behavior
Victor Lukas	Voting Ex-Officio Member, Attending Veterinarian
William Buhles	Voting Member, Public Member
Diane Hoffmann	Voting Member, School of Medicine Sponsored Programs
Fred Jacobsen	Voting Member, Public Member
Johan Leveau	Voting Member, Plant Pathology
Jill Blackwelder-Parker	Non-Voting Ex-Officio Member, Associate Vice Chancellor, Safety Services
Neil Speth	Non-Voting Ex-Officio Member, UCDMC Employee Health Services
Ioannis Stergiopoulos	Voting Member (alternate), Plant Pathology
Roger Belcourt	Voting Ex-Officio Member, Occupational Health Services

I. New Business

A. Amendment (download documents from SmartSite):

BUA No. 347-02(A)		Reviewer: mmm
Titration of <i>Mycobacterium tuberculosis</i> by bacterial culture		

Amendment to add:	Change in procedure: Remove Mtb free tissue culture fluid and cell lysate out from the BSL3 to the BSL2 for further analysis.
-------------------	-------------------------------------------------------------------------------------------------------------------------------

Exp date: **10/21/2016**

APPROVED (8-0-0)

End Time: 9:14 am

Institutional Biosafety Committee, UC Davis
Office of Environmental Health and Safety

MINUTES

July 21, 2014

Hoagland Hall Rm 130

NOTE: Next IBC meeting: 8/18/2014

Start Time: 3:04 pm

In attendance:

Elizabeth Maga	Voting Member, Animal Science (<i>Arrived 3:12pm</i>)
Gerhard Bauer	Voting Member, Vice-Chair, IM Div of Hematology/Oncology (<i>exited meeting 5:18pm</i>)
Johan Leveau	Voting Member, Plant Pathology
Nicole Corley	Voting Member, Campus Veterinary Services
Philip Barruel	Voting Member, Biosafety Officer, Environmental Health and Safety
Renee Tsois	Voting Member, Medical Microbiology & Immunology (<i>Arrived 3:12pm</i>)
Roger Belcourt	Voting Ex-Officio Member, Occupational Health Services (<i>Exited meeting at 3:05pm and returned at 5:05pm</i>)
Sue Bodine	Voting Member, Neurobiology, Physiology, and Behavior
Victor Lukas	Voting Ex-Officio Member, Attending Veterinarian
William Buhles	Voting Member, Public Member

IBC support staff in attendance:

Chips Hoai	Associate BioSafety Officer, Environmental Health and Safety
Malendia Maccree	Associate BioSafety Officer, Environmental Health and Safety
Vivian Xian	Associate BioSafety Officer, Environmental Health and Safety

Excused:

Jill Blackwelder-Parker	Non-Voting Ex-Officio Member, Associate Vice Chancellor, Safety Services
Neil Speth	Non-Voting Ex-Officio Member, UCDMC Employee Health Services
Angela Gelli	Voting Member, Chair, Pharmacology
Bruce Draper	Voting Member, Molecular & Cellular Biology
Diane Hoffmann	Voting Member, School of Medicine Sponsored Programs
Fred Jacobsen	Voting Member, Public Member
Ioannis Stergiopoulos	Voting Member (alternate), Plant Pathology
Lyle Najita	Voting Member, Public Member

Guests:

I. Review of past IBC meeting minutes:

June 16, 2014	<i>APPROVED (7-0-1) JL abst.</i>
July 12, 2015	<i>APPROVED (5-0-4) SB, JL, WB, VL abst.</i>

II. Announcements: NONE

III. Old Business: None

IV. New Business:

BSL2

R	R1477 Replacing 854-01)	APPROVED (8-0-1) <i>abst. GB</i>	Rev: mm
R	R1646 (replacing 990)	APPROVED (9-0-0)	Rev: mm
R	R1679 (replacing 347-01)	APPROVED (9-0-0)	Rev: mm
R	R1682 (replacing 0079)	APPROVED (9-0-0)	Rev: ch
R	R1686 (replacing 979)	APPROVED (9-0-0)	Rev: ch
R	R1689 (replacing 851)	APPROVED (9-0-0)	Rev: ch
R	R1695 (replacing 669)	APPROVED (9-0-0)	Rev: ch
R	R1698 (replacing 978)	APPROVED (9-0-0)	Rev: pb

BBP only

N	R1684	APPROVED (9-0-0)	Rev: mm
R	R1687 (replacing 982B)	APPROVED (9-0-0)	Rev: ch
N	R1691	APPROVED (9-0-0)	Rev: ch

BSL1

R	R1658 (replacing 857)	APPROVED (9-0-0)	Rev: mm
N	R1673	APPROVED (8-0-1) <i>abst. PB</i>	Rev: pb
R	R1681 (replacing 71-01)	APPROVED (9-0-0)	Rev: mm
R	R1693 (replacing 855)	APPROVED (9-0-0)	Rev: ch

Storage Only: NONE

Exempt Protocols: None

B. Amendments (download documents from SmartSite):

BIO amendment (see BIO generated agenda for details):

BUA	R1627	Rev: ch
	APPROVED (9-0-0)	

Amendments on SmartSite (old form):

BUA	51-03(B)	Rev: mm
-----	-----------------	---------

Production of heterologous proteins in plant-based and microbial

Amendment to add:

1. Azotobacter vinelandii Strain OP
2. Klebsiella oxytoca Strain CV2800 (mutant)
3. Klebsiella oxytoca Strain M5al (wild)

Exp date: 6/18/2015

APPROVED (9-0-0)

BUA	75-01(A)	Rev: pb
-----	-----------------	---------

Detection and mechanisms of action of xenobiotic and naturally occurring chemicals / Effect of sEH inhibitors on gingivitis

Amendment to add:

1. Aggregatibacter actinomycetemcomitans

Exp date: 5/21/2015

APPROVED (7-0-2) abst. WB, PB

BUA 84-03(B)

Rev: pb

Selective enrichment of gut bacteria by oligosaccharides

Amendment to add:

1. *Bacteroides* spp. (host: pig)
2. *Escherichia coli* ETEC (host: pig)
3. *Staphylococcus aureus* strains (MRSA, MSSA, VRSA)
4. *Lactobacillus* spp.
5. *Salmonella enterica* (serovar enteritidis)
6. *Enterococcus faecalis*
7. *Listeria monocytogenes*
8. *Pseudomonas aeruginosa*
9. *Klebsiella pneumonia*

Exp date: 10/15/2015

APPROVED (8-0-1) abst. PB

BUA 400(A)

Rev: pb

HIV and SIV Pathogenesis

Amendment to add:

1. Astrovirus (hosts: NHP)

Exp date: 11/19/2015

APPROVED (8-0-1) abst. PB

BUA 492-04 (A)

Rev: mm

Sustained correction of hemophilia A

Amendment to add:

1. Use of human mesenchymal stem cells in mice
2. Transgenic mice (knockout for hemophilia A)

Exp date: 02/25/2016

APPROVED (9-0-0)

BUA 578-02(B)

Rev: pb

Human and transgenic mouse models of Neurologic disorders

Amendment to add:

1. Primary mouse myoblasts
2. Use of lentiviral vectors with reporter genes

Exp date: 07/15/2016

APPROVED (8-0-1) abst. PB

BUA 924-01(A)

Rev: pb

Cellular and molecular mechanisms of neurotoxicity

Amendment to add:

1. Zebrafish as an animal model
2. ish oocyte microinjection
3. Morpholinos RyR2a and p53 and CRISPR-Cas9 knockout
4. Plasmids and siRNA constructs for use in zebrafish

Exp date: 07/05/2016

APPROVED (7-0-1) PB abst., VL stepped out

BUA 1038(A)

Rev: mm

Psychological and biological effects of intensive meditation practice

Amendment to add:

1. Materials in storage only (blood collection has concluded)

Exp date: 02/25/2016

APPROVED (9-0-0)

C. Conditional BUAs reviewed by ABSO, Final Approval by BSO:

R R1628

Rev: ch

Conditional Approval Date: 6/16/14

D. Terminated BUAs: None

BUA 565

Rev: mm

Title: Mouse model of Lyme Borreliosis

BUA 749

Rev: mm

Title: Microbial synthesis and degradation of carbon-14 labeled vitamin B12

BUA 1066

Rev: mm

Title: Auditory transduction in genetically modified mice

D. Terminated BUAs: None

V. Discussion Items:

1. Training renewal frequency/annual training requirements. IBC wanted BBPECP and ATD plans to be read annually, then use the online training modules every three years.
2. Policy decision on ABSL containment requirements animals with viral vectors. Biosafety Office to summarize ABSL containment requirements for review by the IBC at the next meeting.
3. Proposal to create IBC sub-committee for oversight of USDA-APHIS-BRS regulated crop release (coordinated project with USDA, Biosafety Office, Office of Research, CAES and CBS Deans, and faculty). **The IBC voted to form this sub-committee (9-0-0).**

RB returned to meeting

VI. Information Items:

1. Press release from the American Biological Safety Association (ABSA) regarding recent incidents at CDC research labs.

VII. IBC Training: None

VIII. BSL3 Laboratory Information: None

IX. Notifications: None

X. Subcommittee Topics: None

End Time: 5:15p.m.

Institutional BioSafety Committee

Minutes for 07/21/2014

Final

UC Davis

Environmental Health and
Safety

Phone : (530) 752 1493

Fax : (530) 752 4527

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1658	DANIEL KLUEPFEL	PLANT PATHOLOGY	New	BSL: 1 ABSL:

Action: Approved**Review Stage:** Completed**Project Title** Plant-Microbe Interactions and integrated strategies for management of plant disease

Motion

Reviewer	IBC
Review date	July 21, 2014
Comments	APPROVED (9-0-0)
Reviewer	Biostaff
Review date	July 8, 2014
Comments	assigned to mm

Applicable NIH Guidelines

Section	Explanation
IIIE	IIIE2a, b(3) & (4) - use of genetically modified bacterial plant pathogens with plants
IIIF	IIIF8 (App CII) - use of E. coli K12 strains

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1686		VM: ANAT PHYSIO & CELL BIOLOGY	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Protective immunity against typhoid; CD4 T cell responses to Salmonella; Innate Immune response to bacterial flagellins; CD4 response to Chlamydia infection

Motion

Reviewer	IBC
Review date	July 22, 2014
Comments	Approved (9-0-0)
Reviewer	Biostaff
Review date	June 20, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-1-a non-hazardous nucleic acids in salmonella III-D-2-a cloning vaccine candidate genes from salmonella
IIIE	II-E-III I will be generating Cre-Lox mice through a fee for service by the mouse biology program

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1679		MED:PATHOLOGY & LAB MEDICINE	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Molecular and cell studies with infectious agents

Motion

Reviewer	IBC
Review date	July 21, 2014
Comments	APPROVED (9-0-0)
Reviewer	Biostaff
Review date	June 25, 2014
Comments	assigned to mm

Applicable NIH Guidelines

Section	Explanation
IIID	BSL2 rDNA work
IIIE	BL21
IIIF	Ecoli K-12

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1698		NUTRITION	New	BSL: 2 ABSL: 1

Action: Approved

Review Stage: Completed

Project Title Zinc metabolism in humans and animal models

Motion

Reviewer	IBC
Review date	July 21, 2014
Comments	APPROVED (9-0-0)
Reviewer	Biostaff
Review date	July 9, 2014
Comments	assigned to mm

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3B - use of lentiviral vectors in cell lines
IIIE	IIIE3 - generation of transgenic mice which can be housed at ABSL1
IIIF	IIIF8 - purchase and breeding of transgenic mice which can be housed safely at ABSL1

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1628		MED: NEUROLOGY	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Cellular and molecular mechanisms of synapse formation and elimination

Motion

Reviewer	Biostaff
Review date	June 25, 2014
Comments	PI addressed all issues identified by the Committee.
Reviewer	IBC
Review date	June 16, 2014
Comments	<p>CONDITIONAL (11-0-2)</p> <p>The Institutional Biosafety Committee CONDITIONALLY APPROVED your Biological Use Authorization and requests that you submit a revised application that addresses the following points:</p> <ol style="list-style-type: none"> 1. The Committee expressed concern regarding the use of a laminar flow hood for transfections not involving lentivirus or human-derived cell lines. The Committee was uncomfortable with the added risk of having recombinant DNA materials blown directly at the user when working in a laminar flow hood. If a cleaner environment is required, the IBC recommends considering alternatives, such as using a certified biological safety cabinet or plexiglass box for these experiments. 2. The Committee would like to know if non-human primate materials will be used in the laminar flow hood. The risk assessment does not expressly state that these materials will not be used. 3. The Committee would like clarification on how the non-human primate materials will be fixed prior to working on the bench top. 4. The Committee would like the following sentence regarding lentivirus added to the risk assessment, The risk of insertional mutagenesis is possible. 5. In the risk assessment for infectious agents, the Committee would like the word proliferating removed from the second paragraph. 6. In the risk assessment for recombinant DNA methods, the Committee would like the words filter sterilized through be changed to filtered through and amend GFP-transfected cells and LacZ-transfected cells to GFP-transduced cells and LacZ-transduced cells, respectively. 7. In the risk assessment for research materials, the Committee would like no known be changed to unknown and remove the word nonetheless.

Status of BUAs Pending from Previous Meetings - Completed

Reviewer	Biostaff
Review date	May 23, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-1-a, III-D-2-a - lentivirus work
IIIF	III-F-8 (appendix C-II) - plasmids in K12 strains of E. coli

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1689		MED: OTOLARYNGOLOGY	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title The Role of the Inflammatory Process in the Etiology of Labyrinthitis Ossificans

Motion

Reviewer	IBC
Review date	July 21, 2014
Comments	Approved (9-0-0)

Reviewer	Biostaff
Review date	June 27, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1691		MED: OTOLARYNGOLOGY	New	BSL: 2 ABSL: 2+

Action: Approved

Review Stage: Completed

Project Title Applicability of Choroid Plexus Cells for the Repopulation of Hair Cell Depleted Cochlear Sensory Epithelium in the Primate Model

Motion

Reviewer	IBC
Review date	July 21, 2014
Comments	Approved (9-0-0)
Reviewer	Biostaff
Review date	June 30, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1477	GERHARD BAUER	MED: DIV OF INTERNAL MED	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Gene therapy for HIV/AIDS

Motion

Reviewer	IBC
Review date	July 21, 2014
Comments	APPROVED (8-0-1) GB abstain
Reviewer	Biostaff
Review date	August 2, 2013
Comments	Assigned to ND (8/2/2013).

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3b - Use of lentiviral vectors in cells BSL2, Infectious agents, oncogenes, shRNA
IIIF	IIIF8 (AppCII) - Use of E. coli DH5a

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1693	JOHN ROTH	MICROBIOLOGY & MOLEC GENETICS	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title The origin of mutations under selection

Motion

Reviewer	IBC
Review date	July 21, 2014
Comments	Approved (9-0-0)
Reviewer	Biostaff
Review date	June 30, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIIE	III-E-1 - plasmids in attenuated Salmonella
IIIF	III-F-8 appendix C-II - plasmids in E. coli K12

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1682	WOLF HEYER	MICROBIOLOGY & MOLEC GENETICS	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Mechanisms and Regulation of Homologous Recombination

Motion

Reviewer	IBC
Review date	July 21, 2014
Comments	Approved (9-0-0)

Reviewer	Biostaff
Review date	June 18, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-6: 60 L of rDNA culture
IIIE	III-E-1: lipid based transfection methods
IIIF	III-F-8 Appendix C-II, C-III: for E. coli and yeast rDNA experiments

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level	
R1646		COLLEGE BIO SCI DEANS OFFICE	New	BSL: 2+ ABSL:	HIV

Action: Approved

Review Stage: Completed

Project Title Viral co-infection and HIV pathogenesis

Motion

Reviewer	IBC
Review date	July 21, 2014
Comments	APPROVED (9-0-0)
Reviewer	Biostaff
Review date	May 26, 2014
Comments	assigned to mm

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3a - expression of full length HCV virus in cell lines IIID3b - expression of full length HIV virus in cell lines
IIIE	IIIE - use of < 1/2 viral genome in cell lines
IIIF	IIIF8 (app CII) - Use of E. coli K12 strains

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1687	CARLITO LEBRILLA	CHEMISTRY	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Sample preparation for oligosaccharide analysis

Motion

Reviewer	IBC
Review date	July 21, 2014
Comments	Approved (9-0-0)

Reviewer	Biostaff
Review date	June 27, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1681	Jorge Dubcovsky	PLANT SCIENCES	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Wheat Genetics

Motion

Reviewer	IBC
Review date	July 21, 2014
Comments	APPROVED (9-0-0)
Reviewer	Biostaff
Review date	July 1, 2014
Comments	assigned to mm

Applicable NIH Guidelines

Section	Explanation
IIIE	IIIE2a, IIIE2b(3) - Use of Agrobacterium and endemic pathogens with plants
IIIF	IIIF8 (AppCII) - Use of E. coli

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1673		ANIMAL SCIENCE	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Protein expression of loci from the etiologic agent for epizootic bovine abortion (aoEBA)

Motion

Reviewer	IBC
Review date	July 21, 2014
Comments	APPROVED (8-0-1) abst. PB
Reviewer	Biostaff
Review date	July 10, 2014
Comments	1. Pre-review (7/10/2014) PB.

Applicable NIH Guidelines

Section	Explanation
IIIE	This section also includes experiments that dont fall into any other section of the NIH Guidelines, e.g. experiments involving the introduction of Risk Group 1 (RG1) 2 nucleic acid molecules into RG1 organisms such as E. coli BL21

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1627		ANIMAL SCIENCE	Amend	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Production of transgenic and chimeric pigs as medical models

Motion

Reviewer	Biostaff
Review date	May 9, 2014
Comments	Assigned to CH
Reviewer	IBC
Review date	April 21, 2014
Comments	APPROVED (9-0-0)

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-4-a recombinant or synthetic nucleic acids, or DNA or RNA molecules derived therefrom, from any source except for greater than two-thirds of eukaryotic viral genome may be transferred to any non-human vertebrate or any invertebrate organism and propagated under conditions of physical containment comparable to BSL1 or BSL1-N and appropriate to the organism under study; for studies involving transfection of pig embryos with Cas9 mRNA and sgRNA

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1695		MED: DERMATOLOGY	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Galectin-3 in Regulation of Allergic Skin Inflammation

Motion

Reviewer	IBC
Review date	July 21, 2014
Comments	Approved (9-0-0)
Reviewer	Biostaff
Review date	July 2, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-1a - lentivirus, adenovirus III-D-2a - lentivirus, adenovirus
IIIE	III-E-1 - plasmids in mouse cell lines
IIIF	III-F-8 appendix C-II - plasmids in E. coli K12

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1684		MED: OBSTETRICS & GYNECOLOGY	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Discarded human tissues and cells for reproductive research

Motion

Reviewer	IBC
Review date	July 21, 2014
Comments	APPROVED (9-0-0)
Reviewer	Biostaff
Review date	June 18, 2014
Comments	assigned to mmm

Applicable NIH Guidelines

Section	Explanation
None Apply	

Institutional Biosafety Committee, UC Davis
Office of Environmental Health and Safety

MINUTES

August 18, 2014

Hoagland Hall Rm 130

NOTE: Next IBC meeting: 9/15/2014

Start Time: 3:01 pm

In attendance:

Angela Gelli	Voting Member, Chair, Pharmacology
Diane Hoffmann	Voting Member, School of Medicine Sponsored Programs
Fred Jacobsen	Voting Member, Public Member
Gerhard Bauer	Voting Member, Vice-Chair, IM Div of Hematology/Oncology
Ioannis Stergiopoulos	Voting Member (alternate), Plant Pathology
Nicole Corley	Voting Member, Campus Veterinary Services
Philip Barruel	Voting Member, Biosafety Officer, Environmental Health and Safety
Victor Lukas	Voting Ex-Officio Member, Attending Veterinarian

IBC support staff in attendance:

Chips Hoai	Associate BioSafety Officer, Environmental Health and Safety
Malendia Maccree	Associate BioSafety Officer, Environmental Health and Safety
Vivian Xian	Associate BioSafety Officer, Environmental Health and Safety

Excused:

Jill Blackwelder-Parker	Non-Voting Ex-Officio Member, Associate Vice Chancellor, Safety Services
Neil Speth	Non-Voting Ex-Officio Member, UCDMC Employee Health Services
Elizabeth Maga	Voting Member, Animal Science
Bruce Draper	Voting Member, Molecular & Cellular Biology
Johan Leveau	Voting Member, Plant Pathology
Lyle Najita	Voting Member, Public Member
Renee Tsolis	Voting Member, Medical Microbiology & Immunology
Roger Belcourt	Voting Ex-Officio Member, Occupational Health Services
Sue Bodine	Voting Member, Neurobiology, Physiology, and Behavior
William Buhles	Voting Member, Public Member

Guests:

1. **Dr. Primo Lara attended via phone (3:26pm-3:45pm)**
2. **Dr. Beate Crossley, Liz Reay, and Mike Thompson attended (3:46pm-3:57pm)**

I. Review of past IBC meeting minutes:

July 21, 2014 (4-0-4) (F.J, D.H, I.S, and A.G abstained)

Minutes NOT approved (affirmative vote from more than 50% of quorum present required for approval)

II. Announcements: NONE

III. Old Business: None

IV. New Business:

HGT

- N **C1724** *CONDITIONAL (8-0-0)* Rev: mm
1. Principal investigator must complete online training in NIH guidelines compliance requirements.
 2. Bloodborne pathogens training must be completed and/or verified for clinical and pharmacy staff
 3. Full approval of UC Davis IRB must be obtained for this study with the IBC-approved informed consent form and IRB approval letter sent to the Biosafety Office (or uploaded to BIO).

BSL3 (Diagnostic)

- N **R1722** *APPROVED (8-0-0)* Rev: mm

BSL2

- R **R1605** (replacing 990) *APPROVED (8-0-0)* Rev: mm
- R **R1678** (replacing 752) *APPROVED (8-0-0)* Rev: mm
- N **R1688** *APPROVED (8-0-0)* Rev: ch
- R **R1692** (replacing 383) *APPROVED (8-0-0)* Rev: ch
- R **R1696** (replacing 859-01) *CONDITIONAL (7-0-1) abst. PB* Rev: pb
1. Remove animal work from BUA (can be amended later).
 2. Specify source for chimpanzee tissue.
 3. Specify ABSL2 features that will be employed for the work.
- N **R1705** *APPROVED (7-0-1) abst. PB* Rev: pb

BBP only

- R **R1683** (replacing 981B) *APPROVED (9-0-0)* Rev: ch
- R **R1701** (replacing 787-02B) *APPROVED (7-0-1) abst. PB* Rev: pb
- R **R1710** (replacing 988B) *APPROVED (9-0-0)* Rev: ch
- N **R1713** *APPROVED (9-0-0)* Rev: ch
- R **R1714** (replacing 982B) *CONDITIONAL (9-0-0)* Rev: ch
1. Specify source for human tissues and provide any IRB information.
 2. Clarify source of animal tissues and include IACUC information.
- R **R1719** (replacing 980) *CONDITIONAL (7-0-1) abst. PB* Rev: pb
1. Specify source for rat stem cells.
 2. Include IACUC and IRB approval information (If applicable).

BSL1

- R **R1582** (replacing 455) *CONDITIONAL (9-0-0)* Rev: mm
1. Section 1, Project Summary: the primary hypotheses and objectives of this research and the reason for use of transgenic plants in the research must be specified.
 2. Section 4, Biological Materials, Nucleic acids: IBC reviewers requested more information regarding genes that will be investigated,
 3. Section 7, Recombinant DNA, transformation procedures: clarification regarding plant transformations techniques is needed.
- R **R1676** (replacing 35-02) *APPROVED (9-0-0)* Rev: mm
- R **R1685** (replacing 756) *APPROVED (9-0-0)* Rev: ch

Storage Only: NONE

Exempt Protocols: None

B. Amendments (download documents from SmartSite):

BIO amendment (see BIO generated agenda for details):

BUA R1640

Rev: mm

APPROVED (9-0-0)

Amendments on SmartSite (old form):

BUA 226

Rev: pb/vx

Title: Dairy Food Safety Laboratory

Amendment to add:

1. Agent: *Mycoplasma bovis* ATCC 25523
2. Agent: *Mycoplasma californicum* ATCC 33461
3. Agent: *Mycoplasma bovis* ATCC 19852
4. Agent: *Streptococcus agalactiae* ATCC 12401
5. Agent: *Staphylococcus aureus* ATCC 25923
- Procedure/project: QC testing of media room with
6. possible culture of *Mycoplasma spp.*, *Streptococcus spp.*,
E. coli spp., and *Staphylococcus aureus*

Exp date: 11/21/2014

APPROVED (7-0-1) abst. PB

BUA 609(A)

Rev: pb/vx

**Title: Evaluation of Protective Vaccines Against CMV and Other
Opportunistic Infections in Rhesus Macaques**

Amendment to add:

1. *Aggregatibacter actinomycetemcomitans*
2. *Bacterium Bartonella quintana* (strain JK31 wilde type
and recombinant)
3. Blood & tissues from Rhesus monkey infected with
Bartonella quintana
4. Locations for research and storage of materials

Exp date: 4/15/2016

CONDITIONAL (7-0-1) abst. PB

1. Remove Project 1, describing use of human serum samples from
Uganda, from the BUA.

BUA 900-03(E)

Rev: ch

Human pathogenic fungal research

Amendment to add:

1. Procedure: Use of *Candida* strains (already authorized
in BUA) in animal models

2. Procedure: Use of Cryptococcus strains (already authorized in BUA) in animal models

Exp date: 5/21/2015

APPROVED (9-0-0)

BUA 900-03(F)

Rev: ch

Human pathogenic fungal research

Amendment to add:

1. Non-Human primate tissues

Exp date: 5/21/2015

APPROVED (9-0-0)

C. Conditional BUAs reviewed by ABSO, Final Approval by BSO: None

D. Terminated BUAs:

BUA 839

Rev: mm

Title: Storage of: HIV-infected breastmilk, presumptively clade C (South African mothers), Enteropathogenic E. coli, Micrococcus luteus

V. Discussion Items:

1. Use of viral vectors in animals guidance document (Chips) **(APPROVED 8-0-0)**
2. NCURA assessment (Philip)

VI. Information Items: None

VII. IBC Training: None

VIII. BSL3 Laboratory Information:

1. Follow-up actions for J1 insect escape incident (Philip)

IX. Notifications:

1. USDA-APHIS-PPQ Supercontainment Inspection report (Malendia)

X. Subcommittee Topics: None

End Time: 5:37p.m.

Institutional BioSafety Committee

Minutes for 08/18/2014

Final

UC Davis

Environmental Health and
Safety

Phone : (530) 752 1493

Fax : (530) 752 4527

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1710		VM: MOLECULAR BIO SCIENCES	New	BSL: 2 ABSL:

Action: Approved**Review Stage:** Completed**Project Title** Mitochondrial dysfunction in human tissues

Motion

Reviewer	IBC
Review date	August 18, 2014
Comments	APPROVED (8-0-0)
Reviewer	Biostaff
Review date	July 21, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1685	JOANNE ENGEBRECHT	MOLECULAR & CELLULAR BIO	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Meiosis and checkpoint signaling in *C. elegans*

Motion

Reviewer	IBC
Review date	August 18, 2014
Comments	APPROVED (8-0-0)

Reviewer	Biostaff
Review date	June 23, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-4-a for rDNA in <i>C. elegans</i>
IIIF	III-F-8 appendix C-II, C-III for rDNA in K12 <i>E. coli</i> and <i>S. cerevisiae</i>

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1713	LUIS CARVAJAL-CARMONA	MED: BIOCHEM & MOLECULAR MED	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Identification of methylation biomarkers associated with Gastric Cancer

Motion

Reviewer	IBC
Review date	August 18, 2014
Comments	APPROVED (8-0-0)

Reviewer	Biostaff
Review date	August 1, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIIF	III-F-1

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1640		MED: BIOCHEM & MOLECULAR MED	Amend	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Genome Engineering in Mammalian Systems

Motion

Reviewer	IBC
Review date	August 18, 2014
Comments	APPROVED (8-0-0)
Reviewer	Biostaff
Review date	July 17, 2014
Comments	Assigned to MM

Applicable NIH Guidelines

Section	Explanation
IIID	Section III-D-4-a. Recombinant or synthetic nucleic acid molecules, or DNA or RNA molecules derived therefrom, from any source except for greater than two-thirds of eukaryotic viral genome may be transferred to any non-human vertebrate or any invertebrate organism and propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study.
IIIE	Section III-E-1. Recombinant or synthetic nucleic acid molecules containing no more than two-thirds of the genome of any eukaryotic virus may be propagated and maintained in cells in tissue culture using BL1 containment.

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1692		VM: PATHOLOGY MICRO & IMMUN	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Molecular and epidemiologic characterization of bluetongue virus infection in California ruminants

Motion

Reviewer	IBC
Review date	August 18, 2014
Comments	APPROVED (8-0-0)
Reviewer	Biostaff
Review date	June 26, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1719		MED: SURGERY	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Cancer Risk: in vitro and in vivo Studies of Human Adipose Stem Cells on Primary Tumor Breast Cancer Cells

Motion

Reviewer	Biostaff
Review date	September 26, 2014
Comments	Final Approval (pb)
Reviewer	IBC
Review date	August 18, 2014
Comments	CONDITIONAL (7-0-1) PB Abst. * Source of rat stem cells * Indicate IACUC and IRB protocols, if already submitted. * Add for animal housing -
Reviewer	Biostaff
Review date	August 4, 2014
Comments	Assigned to PB

Applicable NIH Guidelines

Section	Explanation
IIID	IIID4a (lentiviral vectors in vertebrate hosts)
IIIE	We will use viral vectors that do not contain more than 1/2 of the genetic material.

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1696		NUTRITION	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Metabolic functions of protein tyrosine phosphatases and their substrates

Motion

Reviewer	Biostaff
Review date	September 30, 2014
Comments	Clarification from researcher: * Animals that are to be housed at ABSL2 will first be transferred to the vivarium for use of the procedure space and for housing (in filter-top caging). * Source of chimpanzee tissue:
Reviewer	IBC
Review date	August 18, 2014
Comments	CONDITIONAL (7-0-1) PB abst. * AAV vector - "insertional mutagenesis" not for viral vector (but for wild type viruses) * Retrovirus vector - add the following hazards: insertional mutagenesis, mucosal contact; add reverse transcriptase inhibitors as recommended treatment * Lentiviral vector - remove "ingestion" and holding period is 48 hrs, not 72 hrs. * Coxsackie virus vector - does not integrate, remove insertional mutagenesis and "direct contact with skin" as a hazard. * Indicate source of chimpanzee tissue. * ABSL2 needs to be defined
Reviewer	IBC
Review date	July 1, 2014
Comments	Assigned to PB

Applicable NIH Guidelines

Section	Explanation
IIID	IIID4a
IIIF	IIIF8 App CI, CII

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1683	NANCY KEIM	NUTRITION	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Improving Public Health by Understanding Diversity in Diet, Brain and Body Interactions.

Motion

Reviewer	IBC
Review date	August 18, 2014
Comments	APPROVED (8-0-0)

Reviewer	Biostaff
Review date	August 4, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1714		NUTRITION	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Impact of dietary lipids on lipid metabolism

Motion

Reviewer	Biostaff
Review date	August 27, 2014
Comments	PI addressed all issues identified by the Committee.
Reviewer	IBC
Review date	August 18, 2014
Comments	<p>CONDITIONAL (8-0-0)</p> <p>The Institutional Biosafety Committee CONDITIONALLY APPROVED your Biological Use Authorization and requests that you submit a revised application that addresses the following points:</p> <ol style="list-style-type: none"> 1. The Committee would like additional information regarding the source of human materials. The application states the samples are obtained through collaborative projects from UC Davis and other national and international research institutes. Please provide what institutions (laboratories) provide each of the materials and whether or not any of these samples will require an IRB approval prior to receipt in your laboratory. 2. The Committee would like additional information regarding the source of animal primary materials. Do any of the materials have an associated IACUC protocol?
Reviewer	Biostaff
Review date	July 25, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1582	SHARMAN O'NEILL	PLANT BIOLOGY	New	BSL: 1 ABSL:

Action: Pending

Review Stage: PI Revise

Project Title Understanding the molecular and genomic basis of plant reproduction, and growth and development.

Motion

Reviewer	IBC
Review date	August 18, 2014
Comments	<p>CONDITIONAL APPROVAL (8-0-0)</p> <p>During the August 18, 2014 meeting, the Institutional Biosafety Committee CONDITIONALLY APPROVED your Biological Use Authorization and requests that you submit a revised application that addresses the following points:</p> <ol style="list-style-type: none"> 1. Section 1, Project Summary: please specify the primary hypotheses and objectives of this research and the reason for use of transgenic plants in the research. 2. Section 4, Biological Materials, Nucleic acids: IBC reviewers requested more information regarding genes that will be investigated, such as: organismal source of genes, examples of gene families that will be examined. The genes of interest may also be described in section 7 under risk assessment for recombinant DNA. 3. Section 7, Recombinant DNA, transformation procedures: There is some ambiguity about whether or not plant transformations will take place in this project. The transformation agent is listed as storage only and plant transformation is described in section 7. If no plant transformations are planned for the immediate future, that should be stated in this section and the BUA will need to be amended to add that work at a later date. If plant transformations are being conducted, IBC reviewers request that more detail be provided in the description of the transformation methods. <p>Conditional Approval means that you may proceed with your work as specified in the BUA, but that you must revise the BUA online record before final approval can be issued.</p>
Reviewer	Biostaff
Review date	August 13, 2014
Comments	Assigned to MM

Applicable NIH Guidelines

Status of BUAs Pending from Previous Meetings - Completed

Section	Explanation
IIIE	IIIE2a - Agrobacterium-mediated plant transformation
IIIF	IIIF8 (app CII) use of E. coli K12 derivatives for cloning of plant genes

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1722		CA ANIMAL HLTH&FOOD SAFETY LAB	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Avian virology in a veterinary diagnostic laboratory

Motion

Reviewer	IBC
Review date	August 18, 2014
Comments	Approved (8-0-0) IBC reviewers requested wording change from "should" to "will". Changes were made to indicate that HPAI culture will be identified with hazards symbols (if known) and workers will report any suspected exposure incidents to Occ Health physician.
Reviewer	Biostaff
Review date	August 13, 2014
Comments	Assigned to MM

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
C1724	PRIMO LARA	MED: DIV OF INTERNAL MED	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title A Phase 2, Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Viagenpumatulcel-L (HS-110) in Combination with Low Dose (Metronomic) Cyclophosphamide Followed by Sequential Chemotherapy Versus Chemotherapy Alone in Patients with Non-Small Cell Lung Adenocarcinoma after Failure of Two Previous Treatment Regimens for Advanced Disease (HS110-201)

Motion

Reviewer	Biostaff
Review date	October 20, 2014
Comments	Biosafety staff (Malendia Maccree) confirmed that PI has met conditions of approval. IRB approval and mandatory annual training materials have been uploaded to attachments section.
Reviewer	IBC
Review date	August 18, 2014
Comments	<p>CONDITIONAL APPROVAL (8-0-0)</p> <p>IBC reviewers requested that wording be added to risk assessment to indicate that needles stick exposure could result in a non-specific immune response at site of injection. (prescriptive wording change made by biosafety office)</p> <p>Additionally, reviewers request that the PI meet following conditions before full approval can be granted:</p> <p>Principal investigator must complete online training in NIH guidelines compliance requirements.</p> <p>Bloodborne pathogens training must be completed and/or verified for clinical and pharmacy staff.</p> <p>Full approval of UC Davis IRB must be obtained for this study with the IBC-approved informed consent form and IRB approval letter sent to the Biosafety Office (or uploaded to BIO).</p>
Reviewer	Biostaff
Review date	August 13, 2014
Comments	Assigned to MM

Applicable NIH Guidelines

Status of BUAs Pending from Previous Meetings - Completed

Section	Explanation
IIIC	Receive approval from IBC, IRB, and RAC review before research participant enrollment.

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1701		MED: DIV OF INTERNAL MED	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Laboratory cancer research; cell line and in vivo xenograft studies

Motion

Reviewer	Biostaff
Review date	September 26, 2014
Comments	App 7-0-1 (PB abst)
Reviewer	Biostaff
Review date	July 10, 2014
Comments	Assigned to PB

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1678	CHONG-XIAN PAN	MED: DIV OF INTERNAL MED	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Leukemia stem cells ligand screening/Bladder cancer ligand screening, imaging/Personalized therapy in NSG mice carrying PDX (new title)

Motion

Reviewer	IBC
Review date	August 18, 2014
Comments	APPROVED (8-0-0) IBC reviewers request that source of human tissues be clarified.
Reviewer	Biostaff
Review date	August 14, 2014
Comments	Assigned to MM

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3b - use of lentiviral vectors in human cells IIID4a - use of recombinant DNA in whole animals (mouse xenografts with transduced and transfected cells)
IIIE	IIIE - use of plasmids in human cells
IIIF	IIIF8 (App CII) - use of E. coli K12 strains

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1676	KENT BRADFORD	PLANT SCIENCES	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Identification, isolation and characterization genes involved in regulation of thermoinhibition and flowering time in lettuce

Motion

Reviewer	IBC
Review date	August 18, 2014
Comments	APPROVED (8-0-0)

Reviewer	Biostaff
Review date	August 15, 2014
Comments	Assigned to MM

Applicable NIH Guidelines

Section	Explanation
IIIE	IIIE2a - Use of Agrobacterium to transfer genes to plants
IIIF	IIIF8 (app CII) - Use of E. coli K12 derivatives

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1605	TREVOR SUSLOW	PLANT SCIENCES	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Study of the microbiological safety of fresh produce

Motion

Reviewer	IBC
Review date	August 18, 2014
Comments	<p>Approved (8-0-0)</p> <p>IBC reviewers requested the following wording changes:</p> <ol style="list-style-type: none"> 1. Remove wording that indicates all isolates used in [REDACTED] are not infectious (reviewers contend that some of the isolates are still technically infectious, but not likely to cause disease in healthy adults). 2. Change wording in project summary about limited project assignments for Shigella. the organism is designated as "storage only" and will require BUA amendment before it can be used in research projects. <p>The above wording changes have been made to the BUA at request of IBC. Please contact the Biosafety office if you find the wording changes unacceptable or if you wish to propose alternative wording.</p>
Reviewer	Biostaff
Review date	August 9, 2014
Comments	Assigned to MM

Applicable NIH Guidelines

Section	Explanation
IIID	IIID1a. Experiments involving the introduction of recombinant or synthetic nucleic acid molecules into Risk Group 2 organisms
IIIE	IIIE- Use of recombinant or synthetic nucleic acid molecules into Risk Group 1 organisms (non-pathogenic)
IIIF	IIIF8 (App CII) - Use of E. coli K12 derivatives (non-pathogenic)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1705		MED:PSYCHIATRY & BEHAV SCI	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Transient manipulation of nonhuman primate brain function using DREADDs

Motion

Reviewer	IBC
Review date	August 18, 2014
Comments	APPROVED (7-0-1) abst. PB
Reviewer	Biostaff
Review date	August 1, 2014
Comments	Assigned to PB for pre-review. Full BUA was finalized in conference with PI and lab staff and reviewed in August IBC meeting (8/18/2014). PI was unable to access BIO system to submit the BUA until 9/15/2014.

Applicable NIH Guidelines

Section	Explanation
IIID	IIID4a (aav)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1688			New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Neural-immune and Brain-gut interactions

Motion

Reviewer	IBC
Review date	August 18, 2014
Comments	APPROVED (8-0-0)
Reviewer	Biostaff
Review date	July 15, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIIE	III-E-1 plasmids in mouse cells
IIIF	III-F-8 appendix C-II Expression of recombinant DNA in E. coli K12

Institutional Biosafety Committee, UC Davis
Office of Environmental Health and Safety

MINUTES

September 5, 2014

Conference call

NOTE: Next IBC meeting: 9/15/2014

Start Time: 10:37 am

In attendance:

Angela Gelli	Voting Member, Chair, Pharmacology
Bruce Draper	Voting Member, Molecular & Cellular Biology
Johan Leveau	Voting Member, Plant Pathology
Lyle Najita	Voting Member, Public Member
Nicole Corley	Voting Member, Campus Veterinary Services
Philip Barruel	Voting Member, Biosafety Officer, Environmental Health and Safety
Renee Tsolis	Voting Member, Medical Microbiology & Immunology
Victor Lukas	Voting Ex-Officio Member, Attending Veterinarian

IBC support staff in attendance:

Malendia Maccree	Associate BioSafety Officer, Environmental Health and Safety
Vivian Xian	Associate BioSafety Officer, Environmental Health and Safety

Excused:

Chips Hoai	Associate BioSafety Officer, Environmental Health and Safety
Sue Bodine	Voting Member, Neurobiology, Physiology, and Behavior
William Buhles	Voting Member, Public Member
Diane Hoffmann	Voting Member, School of Medicine Sponsored Programs
Elizabeth Maga	Voting Member, Animal Science
Fred Jacobsen	Voting Member, Public Member
Gerhard Bauer	Voting Member, Vice-Chair, IM Div of Hematology/Oncology
Jill Blackwelder-Parker	Non-Voting Ex-Officio Member, Associate Vice Chancellor, Safety Services
Neil Speth	Non-Voting Ex-Officio Member, UCDMC Employee Health Services
Ioannis Stergiopoulos	Voting Member (alternate), Plant Pathology
Roger Belcourt	Voting Ex-Officio Member, Occupational Health Services

I. New Business

A. Amendment:

BUA No. **609 (B)** [REDACTED] Reviewer: vx
Title: Evaluation of Protective Vaccines Against CMV and Other
Opportunistic Infections in Rhesus Macaques

Amendment to add:

1. Use of human blood samples obtained from Africa

Exp date: 4/15/2016

APPROVED (8-0-0)

End Time: 11:00 am

Institutional Biosafety Committee, UC Davis
Office of Environmental Health and Safety

MINUTES

September 15, 2014 (3-5pm)

Hoagland Hall Rm 130

NOTE: Next IBC meeting: 10/20/2014

Start Time: 3:00pm

In attendance:

Angela Gelli	Voting Member, Chair, Pharmacology
Diane Hoffmann	Voting Member, School of Medicine Sponsored Programs
Fred Jacobsen	Voting Member, Public Member
Gerhard Bauer	Voting Member, Vice-Chair, IM Div of Hematology/Oncology
Johan Leveau	Voting Member, Plant Pathology
Lyle Najita	Voting Member, Public Member
Nicole Corley	Voting Member, Campus Veterinary Services
Philip Barruel	Voting Member, Biosafety Officer, Environmental Health and Safety
Renee Tsolis	Voting Member, Medical Microbiology & Immunology (<i>arrived 3:21pm</i>)
Sue Bodine	Voting Member, Neurobiology, Physiology, and Behavior
Roger Belcourt	Voting Ex-Officio Member, Occupational Health Services

IBC support staff in attendance:

Chips Hoai	Associate BioSafety Officer, Environmental Health and Safety
Malendia Maccree	Associate BioSafety Officer, Environmental Health and Safety
Vivian Xian	Associate BioSafety Officer, Environmental Health and Safety

Excused:

Jill Blackwelder-Parker	Non-Voting Ex-Officio Member, Associate Vice Chancellor, Safety Services
Neil Speth	Non-Voting Ex-Officio Member, UCDMC Employee Health Services
Elizabeth Maga	Voting Member, Animal Science
Bruce Draper	Voting Member, Molecular & Cellular Biology
Ioannis Stergiopoulos	Voting Member (alternate), Plant Pathology
Victor Lukas	Voting Ex-Officio Member, Attending Veterinarian
William Buhles	Voting Member, Public Member

Guests: NONE

I. Review of past IBC meeting minutes:

July 21, 2014	(6-0-4) APPROVED (FJ, AG, DH, LN abstained)
August 18, 2014	(8-0-2) APPROVED (LN, RB abstained)
Sept 5, 2014	(5-0-5) NOT APPROVED (DH, FJ, SB, GB, RB abstained)

G.B. requested that 9-5-2014 minutes be revised to include major points of discussion
(Vivian will provide discussion notes)

II. Announcements: NONE

III. Old Business: None

IV. New Business:

BSL2

R	R1694 (replaces 670-01, 02)	APPROVED (11-0-0)	Rev: ch
N	R1718	TABLED (11-0-0)	Rev: ch
R	R1721 (replaces 0544-02)	APPROVED (11-0-0)	Rev: ch
R	R1728 (replaces 0755)	APPROVED (11-0-0)	Rev: ch
N	R1737	APPROVED (11-0-0)	Rev: vx
N	R1739	CONDITIONAL (11-0-0)	Rev: mm

1. Obtain a BSC and have it certified for use in the BSL2 lab location.
2. Provide more details of animal surgery and injections, specifically indicating use of needles and scalpels.
3. Describe autoinoculation risks posed to workers.
4. Change animal containment level to BSL2 (with updates to BUA wording and room locations as needed).
5. Revise IACUC protocol and Room Lab Safety Sheet (Appendix A) to reflect changes to the BUA (items 2-4 above).

BBP only

R	R1709 (replacing 0983B)	APPROVED (10-0-1) PB abst.	Rev: pb
R	R1711 (replacing 991B)	APPROVED (11-0-0)	Rev: ch
R	R1736 (replacing)	APPROVED (11-0-0)	Rev: mm

BSL1

R	R1725 (replacing 0469)	APPROVED (9-0-0)	Rev: mm
R	R1726 (replacing)	APPROVED (10-0-1) PB abst.	Rev: pb
R	R1727 (replacing 0376)	APPROVED (9-0-0)	Rev: mm

Storage Only: NONE

Exempt Protocols: None

R	R1732 (replacing 0425)	NO VOTE (EXEMPT)	Rev: mm
---	-------------------------------	-------------------------	---------

B. Amendments (download documents from SmartSite):

BIO amendment (see BIO generated agenda for details):

BUA	R1607	Rev: vx
	CONDITIONAL (11-0-0)	

Add a statement to indicate 1) voles infected with *T. gondii* will be housed in micro-isolator cages and; 2) in addition to lab coat and gloves, surgical mask and face shield will be used when voles infected with *T. gondii* are handled outside a biosafety cabinet, including routine care of the voles.

Amendments on SmartSite (old form):

Amend	0075-01(B)	Rev: vx
-------	-------------------	---------

Detection and mechanism of action of xenobiotics and naturally occurring chemicals- Effects of an epoxide hydrolase inhibitor during the process of blood feeding of
Title: Amendment to add:
1. *Pseudomonas aeruginosa*
2. *Staphylococcus aureus*
3. Procedure to feed mosquitos with the added bacteria listed above

Exp date: 5/21/2015

APPROVED (11-0-0)

Amend 0295-01(A) Rev: pb

Growth and differentiation of airway epithelial cells in response to cytokines and injury
Title: Amendment to add:

1. Influenza Virus A/PR/8/34 (storage only)
2. Adeno-associated virus (AAV): Serotype 1-9, BALs, Lungs and Lung homogenate (storage only)

Exp date: 4/15/2016

APPROVED (10-0-1) PB abst.

Amend 690(D) Rev: vx

The mechanism of action of C. perfringens enterotoxin; C. perfringens type B-D virulence plasmids; In vivo adhesins of Clostridium difficile and Clostridium perfringens
Title: Amendment to add:

1. *Clostridium difficile*
2. Culture of *C. difficile*
3. Experimental infection of mice with *C. difficile*

Exp date: 2/27/15

APPROVED (11-0-0)

Amend 0769(C) Rev: vx

Macaques as a model for influenza and AIDS pathogenesis, transmission, vaccine development and antiviral therapy
Title: Amendment to add:

Storage only of vaccinia virus, modified vaccinia virus Ankara (MVA), measles vector seed stocks, measles virus seed stocks, herpes virus papio, Raji cells, H. papio-transformed monkey B cells (RBCs) and measles vaccine

Exp date: 4/16/16

APPROVED (11-0-0)

Amend 818(A) Rev: pb

Congenital Myasthenic Syndromes: Pathogenic mechanisms
Title: Amendment to add:

1. Lentiviral particles expressing ColQ
2. Transduction of mouse MSCs with lentiviral particles

3. Injecting lentiviral transduced mouse cells expressing ColQ into mice

Exp date: 12/16/2016

APPROVED (10-0-1) PB abst.

C. Conditional BUAs reviewed by ABSO, Final Approval by BSO: None

Amend **609(A)** Reviewer: vx
Conditional Approval Date: 8/18/14

BUA no. **R1597** Reviewer: mm
Conditional Approval Date: 5/19/2014

BUA no. **R1714** Reviewer: ch
Conditional Approval Date: 8/18/14

D. Terminated BUAs:

BUA **640-02** Rev: mm
Title: Evaluation of storox® 2.0 and sanidate® 5.0 as a postharvest disinfection treatment using the smart fog tunnel (tm) system

V. Discussion Items:

1. IBC member alternates (Philip)
2. IBC membership requirements for Dept. of Defense-funded research (Philip)
3. Response from OBA regarding bedding changes for mice w/viral vectors (Chips)
4. Viral Vectors training (Chips)

VI. Information Items: None

VII. IBC Training: None

VIII. BSL3 Laboratory Information:

1. J1 follow-up info - revised SOP (Philip)

IX. Notifications:

1. Sacramento medical waste inspection (Philip)
2. Employee injury with lentiviral vector (with GFP) reportable to NIH-OBA (Philip)
3. National Biosafety Stewardship Month (Philip)

X. Subcommittee Topics: None

1. BQMS: Conference Call with USDA-APHIS-BRS representatives (Malendia)

End Time: 5:37pm

Institutional BioSafety Committee

Minutes for 09/15/2014

Final

UC Davis

Environmental Health and
Safety

Phone : (530) 752 1493

Fax : (530) 752 4527

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1709	ANTHONY WEXLER	MECHANICAL & AEROSPACE ENGR	New	BSL: 2 ABSL:

Action: Approved**Review Stage:** Completed**Project Title** 3D Molecular Imaging of Tissue

Motion

Reviewer	IBC
Review date	September 15, 2014
Comments	APPROVED (10-0-1) PB abst.
Reviewer	Biostaff
Review date	September 8, 2014
Comments	PB pre-review 9/8/2014.

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1711	MAURY HULL	MECHANICAL & AEROSPACE ENGR	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Effects of total knee arthroplasty surgical techniques on tibiofemoral and patellofemoral kinematics and articular surface contact forces

Motion

Reviewer	IBC
Review date	September 15, 2014
Comments	Approved (11-0-0)

Reviewer	Biostaff
Review date	August 25, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1728		VM: MOLECULAR BIO SCIENCES	New	BSL: 2 ABSL: 1

Action: Approved

Review Stage: Completed

Project Title Cell and animal models of mitochondrial disease

Motion

Reviewer	IBC
Review date	September 15, 2014
Comments	Approved (11-0-0)
Reviewer	Biostaff
Review date	September 4, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-1-a and III-D-2-a for lentivirus work
IIIF	III-F-8 Appendix C-II (E. coli K12) and C-III (S. cerevisiae)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1726	JAWDAT AL-BASSAM	MOLECULAR & CELLULAR BIO	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Biochemical and structural studies on the mechanism of microtubule polymerization and depolymerization by regulatory proteins

Motion

Reviewer	IBC
Review date	September 15, 2014
Comments	APPROVED (10-0-1) PB abst.
Reviewer	Biostaff
Review date	September 11, 2014
Comments	PB pre-review (9/11/2014).

Applicable NIH Guidelines

Section	Explanation
IIID	IIID3e (baculovirus)
IIIE	IIIE (E. coli BL21)
IIIF	IIIF8 (App CII - E. coli K-12 strains)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1727	J LAGARIAS	MOLECULAR & CELLULAR BIO	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Molecular Mechanisms of Phytochrome Signaling

Motion

Reviewer	IBC
Review date	September 15, 2014
Comments	APPROVED (11-0-0)
Reviewer	Biostaff
Review date	August 14, 2014
Comments	Assigned to MM

Applicable NIH Guidelines

Section	Explanation
IIIE	IIIE2a - Use of disarmed Agrobacterium to transfer genes to algae and plant hosts
IIIF	IIIF8 (App CII and CIII) - Use of rDNA in E. coli K12 strains and S. cerevisiae

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1718		VM: ANAT PHYSIO & CELL BIOLOGY	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Project Title: Mucosal immunity to RSV infection

Motion

Reviewer	IBC
Review date	October 20, 2014
Comments	APPROVED (11-0-0)
Reviewer	IBC
Review date	September 15, 2014
Comments	<p>Tabled (11-0-0)</p> <p>1. The Committee expressed it was unclear what procedures the PI is proposing to perform with biohazardous materials. Please provide more detailed experimental procedures in Section 7. Experimental Procedures. The Committee was unable to form an appropriate risk assessment from the information provided.</p> <p>2. Please provide a more detailed description of RSV inoculation procedures.</p> <p>3. In Section 2. BUA locations, [REDACTED] mentions the use of Influenza A H1N1, which is not mentioned anywhere else in the protocol. If this was intentional, please add a research description for this agent to the BUA. Please add RSV to the list of agents used in the room.</p>
Reviewer	Biostaff
Review date	August 12, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1721		VM: PATHOLOGY MICRO & IMMUN	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Molecular ecology of avian influenza viruses in wild birds and mammals

Motion

Reviewer	IBC
Review date	September 15, 2014
Comments	Approved (11-0-0)
Reviewer	Biostaff
Review date	August 6, 2014
Comments	Assign to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1736	A HARI REDDI	MED: ORTHOPEDIC SURGERY	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Biomechanical Testing of Human Musculoskeletal Tissues

Motion

Reviewer	Biostaff
Review date	
Comments	Assigned to MM
Reviewer	IBC
Review date	September 15, 2014
Comments	APPROVED (11-0-0)

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1714		NUTRITION	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Impact of dietary lipids on lipid metabolism

Motion

Reviewer	Biostaff
Review date	August 27, 2014
Comments	PI addressed all issues identified by the Committee.
Reviewer	IBC
Review date	August 18, 2014
Comments	<p>CONDITIONAL (8-0-0)</p> <p>The Institutional Biosafety Committee CONDITIONALLY APPROVED your Biological Use Authorization and requests that you submit a revised application that addresses the following points:</p> <ol style="list-style-type: none"> 1. The Committee would like additional information regarding the source of human materials. The application states the samples are obtained through collaborative projects from UC Davis and other national and international research institutes. Please provide what institutions (laboratories) provide each of the materials and whether or not any of these samples will require an IRB approval prior to receipt in your laboratory. 2. The Committee would like additional information regarding the source of animal primary materials. Do any of the materials have an associated IACUC protocol?
Reviewer	Biostaff
Review date	July 25, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1607		VM: MEDICINE & EPIDEMIOLOGY	Amend	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Community ecology of pathogens

Motion

Reviewer	Biostaff
Review date	September 17, 2014
Comments	Per IBC request, Dr. [REDACTED] revised the BUA amendment. Biosafety staff has verified that all IBC comments were addressed, and a final approval was issued for the amendment.
Reviewer	IBC
Review date	September 15, 2014
Comments	<p>CONDITIONAL (11-0-0)</p> <p>At the September 15, 2014 meeting, the Institutional Biological Committee (IBC) reviewed your amendment to BUA #R1607. The Committee granted CONDITIONAL APPROVAL, and requested that you submit a revised application that will address the following comment(s):</p> <p>In the last paragraph of subsection Risk Assessment Infectious Agents, under Section 7 Risk Assessment, add sentences to indicate that 1) voles infected with <i>T. gondii</i> will be housed in micro-isolator cages. 2) A surgical mask and a face shield in addition to lab coat and gloves will be used when voles infected with <i>T. gondii</i> and items that come in contact with the infected voles are handled outside a biosafety cabinet.</p> <p>Conditional Approval means that you may proceed with your work specified in the BUA amendment. However, you must submit a revised document that addresses the above comments by October 1, 2014 for review at the next IBC meeting. If you miss the deadline, the Committee may table your BUA amendment, which will require you to suspend your work until the amendment is approved.</p>
Reviewer	Biostaff
Review date	August 8, 2014
Comments	Assigned to VX

Applicable NIH Guidelines

Status of BUAs Pending from Previous Meetings - Completed

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1739		MICROBIOLOGY & MOLEC GENETICS	New	BSL: 2 ABSL: 2

Action: Pending

Review Stage: IBC

Project Title Role of amoebic trophocytosis in cell killing and tissue invasion by *Entamoeba histolytica*

Motion

Reviewer	IBC
Review date	October 20, 2014
Comments	<p>CONDITIONAL (11-0-0)</p> <p>Institutional Biosafety Committee (IBC) CONDITIONALLY APPROVED your Biological Use Authorization and requests that you submit a revised application that addresses the following points:</p> <ol style="list-style-type: none"> 1. Change animal containment level to ABSL2 (with updates to BUA wording and room locations as needed). 2. Revise IACUC protocol and Room Lab Safety Sheet (Appendix A) to reflect changes to the BUA described above. <p>"Conditional approval" means that the IBC has reviewed the project and will allow it to proceed, provided that the above conditions are fulfilled. Biosafety staff are authorized to verify that the above conditions have been met; the BUA does not need to return to committee unless the PI requests re-evaluation or wishes to propose alternatives to above requirements.</p>
Reviewer	Biostaff
Review date	October 20, 2014
Comments	<p>Response to conditional approval:</p> <p>The principal investigator wishes to contest the IBC requirement to house infected animals at ABSL2. Biosafety staff will work with PI to draft written response to specific concerns noted by IBC reviewers.</p>
Reviewer	Biostaff
Review date	September 26, 2014
Comments	<p>Response to conditional approval from Principal investigator:</p> <p>The principal investigator wishes to house infected animals at ABSL1 because there is no scientific evidence that an infectious organism would be present in the bedding or feces of mice. Principal investigator wishes to provide more background information to support the risk assessment for housing infected animals at ABSL1 and will attend October meeting to answer IBC reviewers questions.</p>

Status of BUAs Pending from Previous Meetings - Completed

Reviewer	Biostaff
Review date	September 15, 2014
Comments	Biosafety staff is working with PI to address requirements for setting up a new BSL2 lab space. Previous occupant has not yet vacated all lab spaces. IBC review of animal work (RLSS) is required prior to review by IACUC. Conditional approval (contingent upon completion of training and purchase/certification of BSC) is recommended by biostaff.
Reviewer	IBC
Review date	September 15, 2014
Comments	<p>CONDITIONAL (11-0-0)</p> <p>IBC reviewers request that PI address the following issues before commencing work:</p> <ol style="list-style-type: none"> 1. Obtain a BSC and have it certified for use in the BSL2 lab location. 2. Provide more details of animal surgery and injections, specifically indicating use of needles and scalpels. 3. Describe autoinoculation risks posed to workers. 4. Change animal containment level to BSL2 (with updates to BUA wording and room locations as needed). 5. Revise IACUC protocol and Room Lab Safety Sheet (Appendix A) to reflect changes to the BUA (items 2-4 above). <p>"Conditional approval" means that the IBC has reviewed the project and will allow it to proceed, provided that the above conditions are fulfilled. Biosafety staff are authorized to verify that the above conditions have been met; the BUA does not need to return to committee unless the PI requests re-evaluation or wishes to propose alternatives to above requirements.</p>
Reviewer	Biostaff
Review date	August 29, 2014
Comments	Assigned to MM

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-1-a Introduction of recombinant or synthetic nucleic acids into Risk Group 2 (RG-2) agents.
IIIF	IIIF8 (AppC-VII) Purchase of transgenic rodents.

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1725	MICHELE IGO	MICROBIOLOGY & MOLEC GENETICS	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title The response of Gram-negative bacteria to environmental changes

Motion

Reviewer	IBC
Review date	September 15, 2014
Comments	APPROVED (11-0-0)
Reviewer	Biostaff
Review date	August 30, 2014
Comments	Assigned to MM

Applicable NIH Guidelines

Section	Explanation
IIIE	IIIE - use of rDNA in Risk Group 1 bacteria
IIIF	IIIF8 (app CII) - Use of rDNA in E. coli K12 strains

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1737		MED:CELL BIOLOGY & HUMAN ANAT	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Investigation of the roles of centrosomes in development and disease

Motion

Reviewer	IBC
Review date	September 15, 2014
Comments	IBC approved (by a vote of 10 to 0) the BUA with the change made listed below: Delete the words or above after BSL2 in the 4th paragraph from the bottom of subsection Experimental Procedures under Section 7 Risk Assessment and Procedures.
Reviewer	Biostaff
Review date	August 27, 2014
Comments	Assigned to VX

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-3-a Use of infectious or defective RG-2 viruses in the presence of helper virus.

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1694		VM: POPULATION HLTH & REPROD	New	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Water and Foodborne Zoonotic Disease Laboratory; Expanding the utility of social network analysis for multilevel health outcomes; Western Center for Food Safety Laboratory; WIFSS

Motion

Reviewer	IBC
Review date	September 15, 2014
Comments	Approved (11-0-0)
Reviewer	Biostaff
Review date	September 4, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1597	ALLEN VAN DEYNZE	PLANT SCIENCES	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Crop Improvement and Disease Resistance

Motion

Reviewer	Biostaff
Review date	August 27, 2014
Comments	ABSO confirmed that PI addressed IBC request in revision of BUA. Final approval issued 8/27/14
Reviewer	IBC
Review date	May 19, 2014
Comments	<p>CONDITIONAL (9-0-1) SB abst.</p> <p>IBC reviewers request that the following points be addressed in revision of your BUA:</p> <ol style="list-style-type: none"> 1. Section 7, experimental procedures: please provide more detail regarding the work conducted with viruliferous leafhoppers, such as the end use of the infected leafhoppers and whether these insects are used to vector virus to plants. 2. Section 4, biological materials--plants: if sunflower plants will be used in this work, please add this plant host to the BUA. 3. Section 4, biological materialsplant virus/viral vector and nucleic acids: please clarify what percentage of the curtovirus genome and/or which viral genes will be transferred to plant hosts. <p>The above points must be addressed before the BUA can receive final approval.</p>
Reviewer	Biostaff
Review date	April 28, 2014
Comments	assigned to mmm

Applicable NIH Guidelines

Status of BUAs Pending from Previous Meetings - Completed

Section	Explanation
IIIE	IIIE2a - Use of Agrobacterium for transgenic plant production and transient expression. IIIE2b(2) - plants in which the introduced DNA represents the complete genome of a non-exotic infectious agent (cortovirus).
IIIF	IIIF8 (App CII) - use of E. coli K 12 strains for routine cloning.

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1732	JAN DVORAK	PLANT SCIENCES	New	BSL: 1 ABSL:

Action: Approved

Review Stage: Completed

Project Title Sequencing the Aegilops tauschii Genome

Motion

Reviewer	IBC
Review date	September 15, 2014
Comments	Exempt from IBC review. IBC notified of exemption in September 15,2014 meeting.
Reviewer	Biostaff
Review date	August 17, 2014
Comments	Assigned to MM

Applicable NIH Guidelines

Section	Explanation
IIIF	IIIF8 (App CII) - Use of non-hazardous rDNA in E. coli K12 strains

Institutional Biosafety Committee, UC Davis
Office of Environmental Health and Safety

MINUTES

September 23, 2014

Conference call

NOTE: Next IBC meeting: 10/20/2014

Start Time: 1:39 pm

In attendance:

Angela Gelli	Voting Member, Chair, Pharmacology
Bruce Draper	Voting Member, Molecular & Cellular Biology
Roger Belcourt	Voting Ex-Officio Member, Occupational Health Services
Lyle Najita	Voting Member, Public Member
Nicole Corley	Voting Member, Campus Veterinary Services
Philip Barruel	Voting Member, Biosafety Officer, Environmental Health and Safety
Elizabeth Maga	Voting Member, Animal Science
Victor Lukas	Voting Ex-Officio Member, Attending Veterinarian

IBC support staff in attendance:

Chips Hoai	Associate BioSafety Officer, Environmental Health and Safety
------------	--------------------------------------------------------------

Excused:

Sue Bodine	Voting Member, Neurobiology, Physiology, and Behavior
William Buhles	Voting Member, Public Member
Diane Hoffmann	Voting Member, School of Medicine Sponsored Programs
Fred Jacobsen	Voting Member, Public Member
Gerhard Bauer	Voting Member, Vice-Chair, IM Div of Hematology/Oncology
Jill Blackwelder-Parker	Non-Voting Ex-Officio Member, Associate Vice Chancellor, Safety Services
Neil Speth	Non-Voting Ex-Officio Member, UCDMC Employee Health Services
Ioannis Stergiopoulos	Voting Member (alternate), Plant Pathology
Renee Tsois	Voting Member, Medical Microbiology & Immunology
Johan Leveau	Voting Member, Plant Pathology
Malendia Maccree	Associate BioSafety Officer, Environmental Health and Safety
Vivian Xian	Associate BioSafety Officer, Environmental Health and Safety

I. Discussion Items:

1. Failure to obtain IBC approval reportable to NIH OBA (Philip)
2. Needle stick lab exposure in Jan Nolte laboratory (Philip)

II. New Business

A. Amendment (documents sent via email on 9/2/14):

BUA No. **0769(D)**



Reviewer: ch

Macaques as a model for influenza and AIDS pathogenesis, transmission, vaccine development and antiviral therapy

Amendment to add:

lactobacillus jensenii 1153 (genetically modified to contain the gene for cyanovirin-N) in macaques

Exp date: **04/16/2015**

APPROVED (8-0-0)

End Time: 1:53 pm

Institutional Biosafety Committee, UC Davis
Office of Environmental Health and Safety

MINUTES

October 20, 2014

Hoagland Hall Rm 130

NOTE: Next IBC meeting: 11/17/2014

Start Time: 3:02pm

In attendance:

Angela Gelli	Voting Member, Chair, Pharmacology
Gerhard Bauer	Voting Member, Vice-Chair, IM Div of Hematology/Oncology
Philip Barruel	Voting Member, Biosafety Officer, Environmental Health and Safety
Sue Bodine	Voting Member, Neurobiology, Physiology, and Behavior
William Buhles	Voting Member, Public Member
Nicole Corley	Voting Member, Campus Veterinary Services
Bruce Draper	Voting Member, Molecular & Cellular Biology
Diane Hoffmann	Voting Member, School of Medicine Sponsored Programs
Fred Jacobsen	Voting Member, Public Member
Lyle Najita	Voting Member, Public Member
Ioannis Stergiopoulos	Voting Member (alternate), Plant Pathology
Thomas Ferguson	Non-Voting <i>Ex-Officio Member</i> , Medical Director, SHCS

IBC support staff in attendance:

Chips Hoai	Associate Biosafety Officer, Environmental Health and Safety
Malendia Maccree	Associate Biosafety Officer, Environmental Health and Safety
Vivian Xian	Associate Biosafety Officer, Environmental Health and Safety

Excused:

Jill Blackwelder-Parker	Non-Voting <i>Ex-Officio</i> Member, Associate Vice Chancellor, Safety Services
Roger Belcourt	Voting <i>Ex-Officio</i> Member, Occupational Health Services
Johan Leveau	Voting Member, Plant Pathology
Neil Speth	Non-Voting <i>Ex-Officio</i> Member, UCDMC Employee Health Services
Elizabeth Maga	Voting Member, Animal Science
Renee Tsolis	Voting Member, Medical Microbiology & Immunology (<i>arrived 3:21pm</i>)
Victor Lukas	Voting <i>Ex-Officio</i> Member, Attending Veterinarian

Guests:

, PI

I. Review of past IBC meeting minutes:

Sept 15, 2014	(10-0-1) APPROVED (BD abstained)
Sept 23, 2014	(6-0-5) APPROVED (SB, WB, DH, FJ, IS abstained)
Sept 5, 2014	Majority vote was not established

II. Announcements: NONE

III. Old Business:

R1718 (Tabled 9/15/2014) **APPROVED (11-0-0)** Rev: ch

R1739 (Conditional 9/15/2014) **CONDITIONAL (11-0-0)** Rev: mm

1. Change animal containment level to ABSL2 (with updates to BUA wording and room locations as needed).
2. Revise IACUC protocol and Room Lab Safety Sheet (Appendix A) to reflect changes to the BUA.

IV. New Business:

A. New and renewal BUAs for review (see BIO generated agenda for details):

N **R1690** **APPROVED (11-0-0)** Rev: ch

N **R1734** **APPROVED (11-0-0)** Rev: mm

R **R1741** (replacing 586-01B) **CONDITIONAL (11-0-0)** Rev: vx

1. Provide the IRB protocol number that will cover the use of human plasma.
2. Specify the source of human plasma to indicate from which laboratory/department the human plasma is coming.
3. Provide the most recent certification date for the biosafety cabinets listed in the attachment.

N **R1747** **TABLED (11-0-0)** Rev: vx

1. Provide a description of the research project, including the purpose of the research project. Indicate what genes will be over expressed and which gene expression will be suppressed.
2. In the "Nucleic Acids" subsection, identify all the transcription factors; Under the "Animals" subsection, provide the name of the transgenic mouse and state what these mice are transgenic for.
3. Provide more details of the experimental procedures, Describe how the materials (listed under section 4) will be used in the procedures. Provide the source of the human cell lines.
4. Complete the BSC Information form under section 8.

AG left the meeting at 4:30 pm, GH started serving as chair, and 10 voting members remained

R **R1757** (Replacing 854-04) **APPROVED (9-0-1, GB abstained)** Rev: ch

N **R1759** **NO VOTE (BUA not required - Withdrawn)** Rev: ch

BBP only

N	R1702	APPROVED (10-0-0)	Rev: ch
N	R1712	APPROVED (10-0-0)	Rev: vx
N	R1755	CONDITIONAL (10-0-0)	Rev: mm

1. Provide most recent date of certification for biosafety cabinet.
2. Revise experimental procedures to include description of biosafety precautions taken when preparing slides.

BSL1

R	R1762 (Replacing 51-05)	CONDITIONAL (10-0-0)	Rev: mm
---	--------------------------------	-----------------------------	---------

1. Provide more details regarding experimental procedures involved in plant transformation.
2. Revise risk assessment to specifically address environmental hazards posed by genetically-modified aquatic plants
3. Provide most recent date of certification for biosafety cabinets in use.

Storage Only

R	R1720 (replacing 0544-01)	APPROVED (10-0-0)	Rev: ch
---	----------------------------------	--------------------------	---------

Exempt Protocols: None

B. Amendments :

BIO amendment:

R1686	CONDITIONAL (10-0-0)	Rev: ch
--------------	-----------------------------	---------

1. Remove information regarding VSV as a helper virus, and remove entry for VSV
2. For the MSCV entry, clarify that the mechanism that prevents replication is "no genes for replication competence present"
3. In the risk assessment, address the risks of working with VSV-g pseudotyped MSCV
4. In the risk assessment, address the risks of auto-innoculation with amphotropic MSCV
5. The IBC would like the PI and all applicable staff to take Viral Vectors training developed by the biosafety staff

R1737	APPROVED (10-0-0)	Rev: vx
--------------	--------------------------	---------

Amendments on SmartSite (old form):

0224(B)	APPROVED (10-0-0)	Rev: vx
----------------	--------------------------	---------

Title: Novel amiloride compounds selectively kill gliomas

Amendment to add:

1. Glioblastoma multiform (GBM) patient-derived xenograft (PDX) cells

Exp date: 12/16/2016

0769(E)	APPROVED (10-0-0)	Rev: ch
----------------	--------------------------	---------

Title: Macaques as a model for influenza and AIDS pathogenesis, transmission, vaccine development and antiviral therapy

Amendment to add:

1. Live-attenuated, double deleted (LADD) strains of *Listeria monocytogenes*
2. Measles Rubella Vaccine
3. Measles Virus (from storage only to active status)
4. Research projects using the added agents

Exp date: 4/16/2016

0833(A)

APPROVED (10-0-0)

Rev. vx

Title: Marine and terrestrial mammal viral disease diagnosis and surveillance

Amendment to add:

1. Clarification: some human blood/serum samples are from HIV+ study participants

Exp date: 11/18/2016

1001(B) NIH: IID3a

APPROVED (10-0-0)

Rev. vx

Title: Systemic and Local Inflammation in Renal Transplantation

Amendment to add:

1. Human kidney, fat, bone and placenta tissues,
2. Ovine kidney, fat, bone and placenta tissues,
3. Rat kidney, fat, bone and placenta tissues
4. Stromal stem cells derived from the above tissues
5. Lentiviral particles carrying GFP or luciferase gene
6. Rat as host for transduced kidneys
7. Research projects using the above added materials

Exp date: 2/27/2015

C. Conditional BUAs reviewed by ABSO, Final Approval by BSO:

R1607 *Conditional Approval Date: 9/20/14*

Rev. vx

D. Terminated BUAs:

0765

Rev. pb

Title: Development of the retinofugal pathways in the ferret

V. Discussion Items:

1. Training frequency requirement for the NIH Guidelines module - Barruel - *postponed*
2. Violations and IBC escalation procedure - Barruel - *postponed*

3. Employee needle stick reportable to NIH-OBA - Barruel: Postdoc got a needlestick injury after re-capping a needle that contained recombinant *Salmonella*. The employee went to Occupational Health and received an antibiotic prescription. PI spoke with employee about working safely and not re-capping the needle. This needs to be reported to NIH OBA.

VI. Information Items: None

VII. IBC Training:

1. Campus emergency management system - Nick Crossley, Campus Emergency Manager
Crossley presented to the IBC a 30 minutes talk on the campus emergency management sys
2. UCDHS BBP training - Barruel - *postponed*
3. Revised VANCHCS Confidentiality and Conflict of Interest Agreements
A copy of the revised VANCHCS Confidentiality and Conflict of Interest Agreements was given to each of the IBC members. Members reviewed and signed the agreement.

VIII. BSL3 Laboratory Information:

1. Follow-up actions for J1 insect escape incident - Barruel

IX. Notifications: None

X. Subcommittee Topics:

1. Draft of BQMS subcommittee charter - Maccree
Draft of BQMS subcommittee charter is being reviewed by USDA and faculty. The draft charter will be available for IBC review on smart site and will be discussed at next meeting.

End Time: 5:33pm

Institutional BioSafety Committee

Minutes for 10/20/2014

Final

UC Davis

Environmental Health and
Safety

Phone : (530) 752 1493

Fax : (530) 752 4527

Track 3: Subcommittee Update

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1747		ENVIRONMENTAL TOXICOLOGY	New	BSL: ABSL:

Action: N/A

Review Stage: IBC

Project Title Ah Receptor regulated gene expression

Motion

Reviewer	IBC
Review date	October 20, 2014
Comments	<p>TABLED (11-0-0)</p> <p>IBC tabled the BUA application #R1747 and requested a revised BUA to address the questions/comments listed below:</p> <p>1) Section 1. Project Summary, provide a short description of the research project, including the purpose of the research project, the AhR (please define) receptor, and the reason why AhR will be studied. Add sentences to indicate what genes will be over expressed, which gene expression will be suppressed, and why these experiments will be conducted.</p> <p>2) Section 4. Biological Materials, is JM 109 a derivative of E. coli K12 strain? If yes, add words to state that. In the table of Cells/Tissues/Body Fluid, provide the name of the transgenic mouse; In the subsection of Nucleic Acids, add words to indicate which of the listed genes or their products are transcription factors; Under subsection of Animals, provide the name of the transgenic mouse and add words to indicate what these mice are transgenic for.</p> <p>3) Section 7. Risk Assessment, expand the subsections of Experimental Procedures and Recombinant DNA to provide more details of the experimental procedures, especially, describe how the materials (listed under section 4. Biological Material) will be used in the procedures, e.g. the mouse/transgenic mouse will be used for generating primary bone marrow derived cells Provide the source of the human cell lines that are listed under section 4.</p> <p>4) Complete the BSC Information form under section 8, Attachments.</p>

Applicable NIH Guidelines

Section	Explanation
IIIE	Experiments not included in Sections III-A, III-B, III-C, III-D, III-F, and their subsections are considered in Section III-E.

Track 3: Subcommittee Update

Section	Explanation
IIIF	III-F-1 synthetic nucleic acids that: (1) can neither replicate nor generate nucleic acids that can replicate in any living cell (e.g., oligonucleotides or other synthetic nucleic acids that do not contain an origin of replication or contain elements known to interact with either DNA or RNA polymerase), and (2) are not designed to integrate into DNA, and (3) do not produce a toxin that is lethal for vertebrates at an LD50 of less than 100 nanograms per kilogram body weight.

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1755	SUBRAMANIAM MURALIDHARAN	MOLECULAR & CELLULAR BIO	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Nanomedicine Nature of Homeopathic Medicines for Cancer

Motion

Reviewer	Biostaff
Review date	October 28, 2014
Comments	Biosafety staff confirmed that PI addressed all conditions of approval. Final approval letter was issued on 11/5/14.
Reviewer	IBC
Review date	October 20, 2014
Comments	<p>CONDITIONAL (10-0-0)</p> <p>Institutional Biosafety Committee CONDITIONALLY APPROVED your Biological Use Authorization and requests that you submit a revised application that addresses the following points:</p> <ol style="list-style-type: none"> 1. Section 7, Risk assessment Infectious agents: Revise experimental procedures to include description of biosafety precautions taken when preparing slides. 2. Section 8, attachmentsbiological safety cabinet information: Provide most recent date of certification for biosafety cabinet. <p>Conditional Approval means that you may proceed with your work as specified in the BUA, but that you must revise the BUA online record before final approval can be issued.</p>
Reviewer	EHS Staff
Review date	September 24, 2014
Comments	Assigned to MM

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1734	OLIVER FIEHN	MOLECULAR & CELLULAR BIO	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Metabolomics Core Facility with Metabolomics Research

Motion

Reviewer	IBC
Review date	October 20, 2014
Comments	APPROVED (11-0-0)

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1762	KAREN MCDONALD	CHEMICAL ENGR & MATERIAL SCI	New	BSL: 1 ABSL:

Action: Pending

Review Stage: PI Revise

Project Title Expression of heterologous proteins in lemnoideae (duckweed)

Motion

Reviewer	IBC
Review date	October 20, 2014
Comments	<p>CONDITIONAL (10-0-0)</p> <p>Conditional approval means that work may continue as described in BUA, but the following conditions must be met before final approval can be issued:</p> <ol style="list-style-type: none"> 1. Section 7, recombinant DNA, transformation methods: Provide more details regarding experimental procedures involved in plant transformation. 2. Section 7, recombinant DNA, risk assessment: Revise risk assessment to specifically address environmental hazards posed by genetically-modified aquatic plants. 3. Section 8, attachmentsbiological safety cabinet information: Provide most recent date of certification for biosafety cabinets in use. <p>Please address the above points within the next month. The IBC may chose to terminate your conditional BUA if the above points are not addressed in a timely manner.</p>
Reviewer	Biostaff
Review date	September 27, 2014
Comments	Assigned to mm

Applicable NIH Guidelines

Section	Explanation
IIIE	IIIE2a - Use of Agrobacterium for plant transformation and in planta expression of heterologous proteins.
IIIF	IIIF8 (App CII) - use of E. coli K12 derivatives

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1702		VM: ANAT PHYSIO & CELL BIOLOGY	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Gamete cryopreservation and micromanipulation of the rhesus macaque

Motion

Reviewer	IBC
Review date	October 20, 2014
Comments	APPROVED (10-0-0)
Reviewer	Biostaff
Review date	September 22, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1718		VM: ANAT PHYSIO & CELL BIOLOGY	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Project Title: Mucosal immunity to RSV infection

Motion

Reviewer	IBC
Review date	October 20, 2014
Comments	APPROVED (11-0-0)
Reviewer	IBC
Review date	September 15, 2014
Comments	<p>Tabled (11-0-0)</p> <p>1. The Committee expressed it was unclear what procedures the PI is proposing to perform with biohazardous materials. Please provide more detailed experimental procedures in Section 7. Experimental Procedures. The Committee was unable to form an appropriate risk assessment from the information provided.</p> <p>2. Please provide a more detailed description of RSV inoculation procedures.</p> <p>3. In Section 2. BUA locations, [REDACTED] mentions the use of Influenza A H1N1, which is not mentioned anywhere else in the protocol. If this was intentional, please add a research description for this agent to the BUA. Please add RSV to the list of agents used in the room.</p>
Reviewer	Biostaff
Review date	August 12, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1686		VM: ANAT PHYSIO & CELL BIOLOGY	Amend	BSL: 2 ABSL: 2

Action: Approved

Review Stage: Completed

Project Title Amendment to use replication-defective viral vectors - Protective immunity against typhoid; CD4 T cell responses to Salmonella; Innate Immune response to bacterial flagellins; CD4 response to Chlamydia infection

Motion

Reviewer	Biostaff
Review date	November 3, 2014
Comments	Final Approval 11/03/2014
Reviewer	IBC
Review date	October 20, 2014
Comments	<p>CONDITIONAL (10-0-0)</p> <p>The Institutional Biosafety Committee CONDITIONALLY APPROVED your Biological Use Authorization Amendment and requests that you submit a revised application that addresses the following points:</p> <ol style="list-style-type: none"> 1. Remove information regarding VSV as a helper virus, and remove entry for VSV 2. For the MSCV entry, clarify that the mechanism that prevents replication is no genes for replication competence present 3. In the risk assessment, address the risks of working with VSV-g pseudotyped MSCV 4. In the risk assessment, address the risks of auto-innoculation with amphotropic MSCV 5. The IBC would like the PI and all applicable staff to take Viral Vectors training developed by the biosafety staff
Reviewer	Biostaff
Review date	October 1, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIID	<p>III-D-1-a non-hazardous nucleic acids in salmonella, MSCV</p> <p>III-D-2-a cloning vaccine candidate genes from salmonella</p> <p>III-D-4-b amphotropic MSCV to create transgenic mice</p>

Status of BUAs Pending from Previous Meetings - Completed

Section	Explanation
IIIE	II-E-III I will be generating Cre-Lox mice through a fee for service by the mouse biology program

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1720	WALTER BOYCE	VM: PATHOLOGY MICRO & IMMUN	New	BSL: ABSL:

Action: Approved

Review Stage: Completed

Project Title Storage Only: Mesocostoides spp. tapeworms, spirometra-type tapeworms, Taenia crossiceps

Motion

Reviewer	IBC
Review date	October 20, 2014
Comments	APPROVED (10-0-0)

Reviewer	Biostaff
Review date	August 25, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1741	BO LONNERDAL	NUTRITION	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Effect of infant formula with bovine osteopontin on infant growth, health and immune function

Motion

Reviewer	Biostaff
Review date	November 13, 2014
Comments	Based on the IBC comments, the BUA was revised to add mouse plasma, delete human plasma and provide the most recent re-certification date for the biosafety cabinet to be used. Biosafety staff has verified that all IBC comments were addressed, and a final approval was issued for the revised BUA.
Reviewer	IBC
Review date	October 20, 2014
Comments	<p>CONDITIONAL (11-0-0)</p> <p>The Committee granted CONDITIONAL APPROVAL. Listed below are the conditions:</p> <p>In Section 4. Biological Materials, 1) provide the IRB protocol number that will cover the use of human plasma; and 2) specify the source of human plasma to indicate from which laboratory/department the human plasma is coming from.</p> <p>In Section 8, attachment Biological Safety Cabinet Information, provide the most recent certification date for the biosafety cabinets listed.</p>

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1712	CASSANDRA CALLOWAY	UNIVERSITY EXTENSION	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Human Forensic Biology Laboratory

Motion

Reviewer	IBC
Review date	October 20, 2014
Comments	APPROVED (10-0-0)
Reviewer	Biostaff
Review date	September 26, 2014
Comments	Assigned to Vivian

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1690		VM: MEDICINE & EPIDEMIOLOGY	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title Generation of a bacterial library related to foal septicemia

Motion

Reviewer	IBC
Review date	October 20, 2014
Comments	APPROVED (11-0-0)
Reviewer	Biostaff
Review date	June 26, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
None Apply	

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1757	GERHARD BAUER	MED: DIV OF INTERNAL MED	New	BSL: 2 ABSL:

Action: Approved

Review Stage: Completed

Project Title GMP grade AAV vector manufacturing

Motion

Reviewer	IBC
Review date	October 20, 2014
Comments	APPROVED (9-0-1) - abs: GB
Reviewer	Biostaff
Review date	September 25, 2014
Comments	Assigned to CH

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-3-e: Use of gene therapy vectors and infectious agents (adenovirus)

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1739		MICROBIOLOGY & MOLEC GENETICS	New	BSL: 2 ABSL: 2

Action: Pending

Review Stage: IBC

Project Title Role of amoebic trophocytosis in cell killing and tissue invasion by *Entamoeba histolytica*

Motion

Reviewer	IBC
Review date	October 20, 2014
Comments	<p>CONDITIONAL (11-0-0)</p> <p>Institutional Biosafety Committee (IBC) CONDITIONALLY APPROVED your Biological Use Authorization and requests that you submit a revised application that addresses the following points:</p> <ol style="list-style-type: none"> 1. Change animal containment level to ABSL2 (with updates to BUA wording and room locations as needed). 2. Revise IACUC protocol and Room Lab Safety Sheet (Appendix A) to reflect changes to the BUA described above. <p>"Conditional approval" means that the IBC has reviewed the project and will allow it to proceed, provided that the above conditions are fulfilled. Biosafety staff are authorized to verify that the above conditions have been met; the BUA does not need to return to committee unless the PI requests re-evaluation or wishes to propose alternatives to above requirements.</p>
Reviewer	Biostaff
Review date	October 20, 2014
Comments	<p>Response to conditional approval:</p> <p>The principal investigator wishes to contest the IBC requirement to house infected animals at ABSL2. Biosafety staff will work with PI to draft written response to specific concerns noted by IBC reviewers.</p>
Reviewer	Biostaff
Review date	September 26, 2014
Comments	<p>Response to conditional approval from Principal investigator:</p> <p>The principal investigator wishes to house infected animals at ABSL1 because there is no scientific evidence that an infectious organism would be present in the bedding or feces of mice. Principal investigator wishes to provide more background information to support the risk assessment for housing infected animals at ABSL1 and will attend October meeting to answer IBC reviewers questions.</p>

Status of BUAs Pending from Previous Meetings - Completed

Reviewer	Biostaff
Review date	September 15, 2014
Comments	Biosafety staff is working with PI to address requirements for setting up a new BSL2 lab space. Previous occupant has not yet vacated all lab spaces. IBC review of animal work (RLSS) is required prior to review by IACUC. Conditional approval (contingent upon completion of training and purchase/certification of BSC) is recommended by biostaff.
Reviewer	IBC
Review date	September 15, 2014
Comments	<p>CONDITIONAL (11-0-0)</p> <p>IBC reviewers request that PI address the following issues before commencing work:</p> <ol style="list-style-type: none"> 1. Obtain a BSC and have it certified for use in the BSL2 lab location. 2. Provide more details of animal surgery and injections, specifically indicating use of needles and scalpels. 3. Describe autoinoculation risks posed to workers. 4. Change animal containment level to BSL2 (with updates to BUA wording and room locations as needed). 5. Revise IACUC protocol and Room Lab Safety Sheet (Appendix A) to reflect changes to the BUA (items 2-4 above). <p>"Conditional approval" means that the IBC has reviewed the project and will allow it to proceed, provided that the above conditions are fulfilled. Biosafety staff are authorized to verify that the above conditions have been met; the BUA does not need to return to committee unless the PI requests re-evaluation or wishes to propose alternatives to above requirements.</p>
Reviewer	Biostaff
Review date	August 29, 2014
Comments	Assigned to MM

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-1-a Introduction of recombinant or synthetic nucleic acids into Risk Group 2 (RG-2) agents.
IIIF	IIIF8 (AppC-VII) Purchase of transgenic rodents.

Status of BUAs Pending from Previous Meetings - Completed

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1737		MED:CELL BIOLOGY & HUMAN ANAT	Amend	BSL: 1 ABSL: 1

Action: Approved

Review Stage: Completed

Project Title Investigation of the roles of centrosomes in development and disease

Motion

Reviewer	IBC
Review date	October 23, 2014
Comments	APPROVED (10-0-0)

Applicable NIH Guidelines

Section	Explanation
IIID	<p>III-D-3-a Use of infectious or defective RG-2 viruses in the presence of helper virus.</p> <p>Section III-D-4-a. Recombinant or synthetic nucleic acid molecules, or DNA or RNA molecules derived therefrom, from any source except for greater than two-thirds of eukaryotic viral genome may be transferred to any non-human vertebrate or any invertebrate organism and propagated under conditions of physical containment comparable to BL1 or BL1-N and appropriate to the organism under study.</p>

Status of BUAs Pending from Previous Meetings - Withdrawn

BUA#	Principal Investigator	Department	Request Type	Biosafety Level
R1759		VM: ANAT PHYSIO & CELL BIOLOGY	New	BSL: 2 ABSL: 2

Action: Withdrawn

Review Stage: Completed

Project Title Role of sexual dimorphisms in BBB permeability on CNS autoimmunity.

Motion

Applicable NIH Guidelines

Section	Explanation
IIID	III-D-4-b The experiments described in the project summary will involved the use of synthetic nucleic acids to determine gene expression. Also, experiments involved whole animals and are not covered by Sections III-D-1 or III-D-4-a.

